HAL
open science

Optogenetics for light control of biological systems

Valentina Emiliani, Emilia Entcheva, Rainer Hedrich, Peter Hegemann, Kai Konrad, Christian Lüscher, Mathias Mahn, Zhuo-Hua Pan, Ruth Sims, Johannes Vierock, et al.

To cite this version:

Valentina Emiliani, Emilia Entcheva, Rainer Hedrich, Peter Hegemann, Kai Konrad, et al.. Optogenetics for light control of biological systems. Nature Reviews Methods Primers, 2022, 2, pp.55. 10.1038/s43586-022-00136-4 . hal-03772021

HAL Id: hal-03772021

https://hal.sorbonne-universite.fr/hal-03772021v1

Submitted on 7 Sep 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Optogenetics for light control of biological systems

Valentina Emiliani[1], Emilia Entcheva[2], Rainer Hedrich[3], Peter Hegemann[4†], Kai R. Konrad[3], Christian Lüscher[5], Mathias Mahn[6], Zhuo-Hua Pan[7], Ruth Sims[1] Johannes Vierock[4], Ofer Yizhar[8]

Authors are listed in alphabetical order

[1] Wavefront Engineering Microscopy Group, Photonics Department, Institut de la Vision, Sorbonne Université, INSERM, CNRS, Paris, France

[2] Department of Biomedical Engineering, George Washington University, Washington, DC, USA

[3] Julius-von-Sachs Institute for Biosciences, Molecular Plant Physiology and Biophysics, University of Wuerzburg, Wuerzburg, Germany

[4] Institute for Biology, Experimental Biophysics, Humboldt-Universitaet zu Berlin, Berlin Germany

[5] Department of Basic Neurosciences, Faculty of Medicine, University of Geneva, Geneva, Switzerland; Clinic of Neurology, Department of Clinical Neurosciences, Geneva University Hospital, Geneva, Switzerland.

[6] Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland.

[7] Department of Ophthalmology, Visual and Anatomical Sciences, Wayne State University School of Medicine, Detroit, USA

[8] Department of Brain Sciences, Weizmann Institute of Science, Rehovot, Israel

[†]Email: Hegemann@rz.hu-berlin.de

Abstract:

Optogenetic techniques have been developed to allow control over the activity of selected cells within a highly heterogeneous tissue, using a combination of genetic engineering and light. Optogenetics employs natural and engineered photoreceptors, mostly of microbial origin, to be genetically introduced into the cells of interest. As a result, cells that are naturally light-insensitive can be made photosensitive and addressable by illumination and precisely controllable in time and space. The selectivity of expression and subcellular targeting in the host is enabled by applying control elements such as promoters, enhancers, and specific targeting sequences to the employed photoreceptor-encoding DNA. This powerful approach allows precise characterization and manipulation of cellular

functions and has motivated the development of advanced optical methods for patterned photostimulation. Optogenetics has revolutionized neuroscience during the past 15 years and is primed to have a similar impact in other fields, including cardiology, cell biology and plant sciences. In this Primer we describe the principles of optogenetics, review the most commonly used optogenetic tools, illumination approaches and scientific applications and discuss the possibilities and limitations associated with optogenetic manipulations across a wide variety of optical techniques, cells, circuits and organisms.

[H1] Introduction

Light-dependent processes are abundant in nature, occurring in diverse organisms from bacteria and algae to plants and animals and are used for energy capture and storage, to regulate developmental processes and to mediate orientation[1-3]. While the photoreceptors involved in light-sensing have been studied for decades, the use of such proteins for actuation of naturally light-insensitive cells began only in 2002 with the expression of the Drosophila rhodopsin and its associated signaling proteins in neurons[4]. The discovery of channelrhodopsin, identified in the same year in the green alga Chlamydomonas, in conjunction with the almost universal cellular availability of the chromophore all-trans retinal (Vitamin A) in most cells and organisms, accelerated the progress of this new technology. Almost in parallel with the initial application of Channelrhodopsin-2 (ChR2) in isolated neurons in 2005[5] and brain slices in 2006[6], ChRs were rapidly adapted for use in living model organisms, including chicken embryos[7] and *C. elegans* in 2005 ref[8], Drosophila in 2006 ref[9], freely moving mice in 2007 ref[10], zebrafish in 2008 ref[11] and even non-human primates in 2009 ref[12]. The first experiments that pointed toward potential therapeutic applications were performed in 2006, pioneered by the expression of ChR in inner retinal cells to restore vision in blind mice[13]. Optogenetics is based on sensory photoreceptors sequences from microalgae, fungi or bacteria. But, only the combination of photoreceptor-encoding DNA with control elements like promoters and targeting sequences, typically derived from genes expressed selectively in target, allows the protein allows specificity not only in the choice of target cell population but also in the subcellular compartments to be manipulated. The DNA-constructs are incorporated into target cell populations, tissues or living

organisms using vectors such as plasmids, viral vectors or bacteria using established transformation technologies (Fig. 1).

The robust function and revolutionary utility of ChR2 in neuroscience resulted in the description and application of many photoreceptor subtypes, engineered or retrieved from genomic or cDNA databases, progress in protein expression and targeting, microelectrode **[G]** and optrode **[G]** technology, and finally the combination of optogenetic actuators **[G]** with optical fluorescent reporter systems and high-resolution subcellular imaging, accelerating the interdisciplinary growth of optogenetic technology with unprecedented pace. The need to control neuronal activity with increased spatial resolution has in turn motivated the development of advanced optical methods for patterned photostimulation. Digital mirror devices (DMD) or liquid crystal spatial light modulators (LC-SLM) coupled to single or two-photon excitation have enabled single and multi-target excitation in vitro and in vivo with single-spike precision and cellular resolution in head-restrained and freely-moving animals[14]. Optogenetics has developed as a basic science methodology for dissecting biological functions; while it has initially been adopted by neuroscientists to study brain function and dysfunction, it has expanded into new research fields such as cardiology, microbiology, immunology, parasitology and plant science. These developments are culminating in highly-anticipated clinical applications, as envisioned in the early days of optogenetics, including multiple clinical trials currently in progress for selected human disorders. A crude timeline of key breakthroughs in optogenetic technology is displayed in Figure 2.

With the growth of optogenetic technology came an abundance of tools with diverse functional properties. This Primer is focused predominantly on rhodopsin-based optogenetic tools, which are the most widely used within the growing optogenetic toolbox. While the differences between tools can be subtle, their spectral sensitivity, kinetic properties and ion selectivity can have a major influence on the outcome of an optogenetic experiment. Understanding these features and careful design are therefore crucial for the success and interpretability of optogenetic experiments. As the technology matures and gains popularity across multiple fields of biology, this Primer aims to provide experimentalists with the most relevant knowledge needed to design, perform, and interpret optogenetic experiments.

[H1] Experimentation

Optogenetic experiments are based on the combination of several fundamental components: a genetically-encoded actuator that, after reconstitution with an organic molecule serving as chromophore, responds to light and can be used to influence the function of the tool-expressing cell or tissue in a light dependent manner; a light source providing light at the appropriate wavelength and intensity; and a light-delivery system, which allows for illumination of targeted cells for temporally-precise activation of the optogenetic actuator. Together, these components allow the experimenter to modulate the biological system and interrogate its function.

[H2] Selecting the correct actuator

When designing an optogenetic experiment, the first considerations should be the cellular parameter to be modulated and the available optogenetic actuators for such an endeavor. An enormous number of light-switchable tools have been developed for controlling ion fluxes and membrane voltage, G-protein signaling, regulation of second messengers such as Ca^{2+}, cAMP, cGMP, IP3, receptor tyrosine kinases (TRKs), organelle repositioning, transcription and translation (Fig. 2). Most actuators rely on photoreceptors or light sensing modules of natural origin, although photoswitchable synthetic organic compounds have also been employed[15]. The use of photoswitchable synthetic organic compounds is also known as chemooptogenetics or photopharmacology, and the interested reader might consult related reviews[15,16]. Many light-modulated actuators have been described that do not rely on opsin proteins. While this Primer is focused on the opsin-based toolbox, the reader might find more information about non-opsin-based optogenetic tools in several excellent recent reviews[17,18].

[H3] Light-activated ion channels

Until recently the most widely applied optogenetic photoreceptor was Channelrhodopsin-2 from the alga *Chlamydomonas reinhardtii* (known as *Cr*ChR2 or simply C2) and its variant ChR2-H134R[8,19]. Presently, almost 900 ChR sequences have been identified, including many with properties superior to those of the original prototypes (Figure 2)[20]. ChRs may be subdivided into cation or anion conducting channels, termed CCRs and ACRs respectively. CCRs typically conduct multiple types of cations with high preference for protons. Na^{+} selectivity varies widely among different CCRs[21] and divalent cations are only poorly conducted under most physiological host conditions. Whereas there are no Ca^{2+}-selective CCRs available to date, continuous metagenomic screening recently revealed a

124 new class of potassium selective channels (KCRs)[22]. ACRs are selective for a number of anions,
125 similar to most human anion channels[23].
126 In host cells, Na^+ and H^+-conducting CCRs can be used as depolarizing actuators, whereas the
127 action of ACRs depends on the chloride reversal potential in the targeted cells or subcellular
128 compartment (Box 1). ACRs may clamp the voltage to near the resting potential and inhibit action
129 potential firing by shunting inhibition (Box 1). However, in cardiac cells, immature neurons and
130 presynaptic terminals, chloride gradients are less pronounced and ACRs may depolarize the cell
131 membrane [24,25]. In plants, the chloride gradient is always directed outward, and ACR activation will
132 generally lead to membrane depolarization. Thus far, KCRs have been applied under highly controlled
133 in vitro conditions, but -— once established for in vivo experiments — hold major promise for
134 optogenetic inhibition in all variants of cells and host model systems.
135 Our current molecular understanding of ChRs mostly relies on *Cr*ChR2, which has been
136 extensively studied and modified with respect to kinetics, ion selectivity, inactivation and absorption
137 wavelength [26,27] revealing principles that have been successfully transferred to other CCRs
138 (Supplementary Figure 1). Recently discovered channelrhodopsins such as ChRmine and KCRs
139 belonging to a new family of cation conducting ChRs hold great promise, but understanding of their
140 molecular mechanism is only beginning to emerge[28,29]. The maximal color sensitivity of known ChRs
141 so far spans from 445 nm for *Ts*ChR to 610 nm for the ChrimsonSA mutant and Ruby-ACR[30-32]
142 (Figure 2). Such distinct color sensitivity may allow the combination of different ChRs within the
143 same experiment for activation and inhibition of the same or different cells. However, all rhodopsins
144 absorb blue or UVA light to a certain extent due to transition to higher excited state levels. This has
145 to be taken into consideration when combining multiple rhodopsins in a single or multiple cell
146 populations (Supplementary Figure 2). For bidirectional voltage modulation **[G]** for example, the
147 more potent actuator should be selected to absorb at the shorter wavelength (Figure 2) thereby
148 allowing for lower light powers used in the blue range, which will in turn minimize the undesired
149 activation of the red-shifted actuator. Another consideration is the reversal potential of the conducted
150 ion. In nature, as well as in neuronal experiments, ACRs operate closer to the reversal potential than
151 Na^+ or H^+ conducting depolarizing CCRs. While it is possible to co-express two opsins using two
152 separate viral vectors, this approach inevitably leads to incomplete co-expression in all cells. To
153 overcome this draw back, several constructs have been engineered which allow tandem expression of
154 two opsins from the same vector. The most prominent examples are eNPAC which coexpresses

eNpHR3.0 and ChR2(H134R) initially linked by a 2A selfcleaving peptide[33], and BiPOLES[34], which combines the red-shifted CCR Chrimson with the blue-shifted GtACR2 in a single targeting-optimized fusion contruct[35]. Due to the stoichiometric membrane expression, equal photocurrents near the cellular resting potential and comparable light sensitivities of both channel modules, BiPOLES outperforms previous bicistronic combinations of ChR2 with different ion pumps[59,60] and guarantees subcellular colocalization and selective red-light excitation for multicolor applications. A combination of optogenetics and chemogenetics has been exemplified by direct fusion of slow cycling step function rhodopsins (SFOs) with a luciferase that produces light upon peripheral injection of its small molecule substrate. These luminopsins allow direct light stimulation by optical fibers, while at the same time providing chemogenetic access in awake and anesthetized animals in vivo[61,62].

[H3] Light-driven pumps

The first application of optogenetics for neuronal silencing was achieved with the chloride pump halorhodopsin [36]. However, since the discovery of ACRs, the interest in optogenetic silencing of animal cells by light-driven pumps has decreased in animal cells because pumps require higher expression levels and higher light intensities for sufficient ion turnover (Supplementary Figure 3). In contrast, in plants — which naturally hyperpolarize their membranes and drive secondary transporters via H^+ pumps — light-driven H^+ pumps are valuable tools. The advantage of light-driven pumps is their high ion specificity and robust electric response that depends less on the ionic composition of the surrounding buffers and the membrane voltage. Light-driven chloride pumps such as NpHR [37] or Jaws [38] allow reliable — although often weak — neuronal inhibition in synaptic terminals, where the action of ACRs is difficult to predict due to variable and elevated intracellular chloride concentrations [39]. Pumps may be successfully used in small compartments such as neuronal vesicles, lysosomes[40], mitochondria or thylakoids, where the action of ion channels is poorly defined due to the lack of free ions[41]. In the plasma membrane the use of light-driven ion pumps requires caution because both proton and chloride pumps can drive non-physiological ion concentrations in neurons and trigger off-target effects, including a transient increase of the chloride reversal potential, leading to excitatory actions of the inhibitory neurotransmitter GABA and alkalization of presynaptic terminals, leading to increased spontaneous neurotransmission [39,42].

[H3] Optogenetic control of biochemical signaling pathways

186 Animal rhodopsins are G-protein coupled receptors (GPCRs) and animal vision is the most studied
187 G-protein signaling pathway. A pioneering study demonstrated that bovine rhodopsin expression may
188 be used to activate G-protein signaling in Xenopus oocytes but without describing the signaling
189 mechanism[43]. However, the off-response of rod-rhodopsins remained uncontrollable in the absence
190 of rhodopsin kinase and Arrestin, and responses severely declined upon repetitive stimulation. The
191 responses of $G_{i/o}$ activating cone rhodopsins [44-46] or Gs-specific box jellyfish opsins [47] declined faster,
192 but were still not tightly controllable. The solution was approached by revitalizing melanopsin OPN4,
193 which can be switched on and off with blue and yellow light, albeit incompletely due to substantial
194 overlapping spectra of the dark-state and signaling-state [48-50] and only the UV-sensitive Lamprey
195 Parapinopsin (PPO) with its green-absorbing signaling state offered efficient on and off switching
196 with a dual color light source [51-54].

197 GPCR signaling depends on many properties of the receptors, including substrate binding
198 kinetics, G-protein specificity and timing of activation and receptor inactivation, which in total cannot
199 be fully mimicked by rhodopsins. One way to more selectively mimic the activity of a specific GPCR
200 is to engineer hybrids between structurally related opsins and GPCRs (optoGPCRs) [55,56]. OptoGPCRs
201 open new and possibly more specific routes for the analysis of intracellular signaling pathways
202 compared to unmodified rhodopsins whereas the dynamics of G-protein coupling and pathway
203 recruitment still has to be approached by testing various expression levels and light regimes. However,
204 these optoGPCRs cannot be simply transferred to another cell type because G-protein promiscuity
205 might activate unwanted pathways [48,57]. With OptoGPCRs the application of G-protein activation has
206 enormously broadened the optogenetic actuator toolbox. These tools will be well-suited for
207 temporally-defined modulation of non-excitable cells, potentially including glial cells in the brain and
208 other non-neuronal cell types [58].

209 Receptor tyrosine kinases (RTKs) are another large family of cell surface receptors that sense
210 growth factors and hormones to regulate a variety of cellular behaviors by target phosphorylation.
211 Engineered light sensitive epidermal growth factor receptor (EGFR1) and the fibroblast growth factor
212 receptor 1 (FGFR1) have shown robust light activation of both RTK-receptors and cellular signaling
213 in human cancer and endothelial cells and faithful mimicking of complex mitogenic and morphogenic
214 cell behavior [59]. Cobalamin-binding domain (CBD) and tropomyosin receptor kinase B (TrkB) have
215 been fused to RTKs to yield light-sensitive receptors[60,61]. Fusions with TrkB have high specificity for
216 the target proteins, although their application range is narrow and the constructs need to be optimized

for every new application. Moreover, one drawback is that cobalamin-based light sensors or phytochrome-based light sensors generally require addition or cellular synthesis of the cofactor molecules, making their potential for in vivo applications more complex than the application of the retinal-based photoreceptors.

[H3] Second messengers

Photoactivated cyclases (PACs) have been employed for direct control of the second messengers cAMP and cGMP. The soluble bPAC from *Beggiatoa spp*. is a tandem of BLUF-type light sensors (blue-light sensors using FAD (Flavin adenine dinucleotide) (Figure 2) with C-terminal adenylyl cyclases. These optogenetic actuators show millisecond-range on-kinetics upon photostimulation and a second-range off-kinetics in the dark (bPAC τ_{off} = 12 s)[62]. Coexpression of bPAC with the small prokaryotic potassium-channel SthK (PAC-K silencer) in two-component optogenetic approaches has been exploited for long lasting neuronal hyperpolarization in cardiomyocytes as well as in fly, mouse and zebrafish neurons providing high operational light sensitivity but low time resolution [62-65]. However, color modification is only possible within a small range around 470 nm and occasional residual dark activity has been observed [66]. New spectral windows were opened by introducing Rhodopsin Guanylyl Cyclases (RGCs), which are cyclases with N-terminally linked rhodopsins. These rhodopsin-cyclases (RhCs) are characterized by low dark-activity, effective light absorption ($\varepsilon > 32000\ M^{-1}cm^{-1}$) and the promise of flexible color tuning [67-69]. RhCs show millisecond-range off-kinetics, are naturally GTP selective and are convertible into ATP cyclases by genetic engineering. Some members of the fungal Chytridiomycota may use heterodimeric RhGCs, with one blue or green sensitive rhodopsin catalyst, and a second near infrared sensitive modulator (NeoR, λ_{max} = 660–700 nm). These NeoRs might allow to extend the usable spectral range into the superior infrared spectral window [70].

[H3] Protein abundance

Control over the concentration of selected proteins within a cell has been a long-standing goal, and has stimulated the interest of protein engineers for decades. The most obvious point of intervention is the regulation of transcription. Previously explored concepts were based on the connection of DNA-binding proteins to a photoreceptor such as Phytochrome, FKF1 or VIVID (LOV-proteins), or CRY. Upon illumination, these photoreceptors bind to their signaling partner proteins PIF3,

GIGANTEA/Tulips or CIB respectively, with bound components of the transcription machinery as VP16 or VP64. In light, the transcription component is attracted to the promoter region of interest by the photoreceptor and signal-protein interaction leading to the assembly of the transcription complex and initiation of transcription. But, the used GAL4-DNA binding domains have to be incorporated into the model organism (reviewed in[71,72]). To address any promoter of interest, programmable DNA-binding proteins zinc finger-DNA binding proteins[73], TALEs[74] and deactivated Cas9 have been functionalized as the second generation of transcription regulators[75,76]. The main caveat for Cas9 application is the prolonged occupancy of Cas9 at its DNA binding site, especially in situations where the DNA is not cleaved, which disturbs gene expression prior to the intended start of the experiment[77]. Inserting a LOV-domain into an anti-CRISPR protein like AcrIIA4 or AcrIIC3 (CASANOVAs) overcomes this problem and makes Cas9 binding better controllable. This approach works reliably in HEK cells, but has not been rigorously tested for non-embryonic cells such as neurons [104].

[H2] Targeting strategies

Optogenetics was first applied in neuroscience, driven by the complexity of neural circuits and the demand for improved selectivity in perturbational approaches for studying neural circuits. Genetic techniques, viral vector technology and optical methods have grown rapidly around the developing optogenetic toolbox. As a result, the tools and enabling technologies for optogenetic experimentation in neuroscience, as well as the fundamental understanding of the caveats and constraints of their application, are more advanced in neuroscience than in other fields. In the following section, we review some of the major targeting approaches for expression of optogenetic tools in neural circuits.

One of the major benefits of the optogenetic paradigm is its selectivity to defined cells and circuits. In neuroscience applications, genetic targeting of optogenetic tools has advanced considerably, and has profited greatly from developments in viral vector technologies. Since optogenetic tools are genetically-encoded and mostly single-component actuators (requiring the introduction of only one gene to the target cell population), multiple delivery methods can be used to introduce them into the cells of interest. Targeting strategies are either based on promoter specificity directly, or through a combination of a conditional transgene expression cassette that can be switched on or off using a recombinase.

[H3] **Transgenic expression of optogenetic tools**

Transgenic expression is the simplest approach to implement since it requires only the maintenance of an opsin-expressing animal strain (Figure 3a) [78] or the crossing of two strains of animals. The latter involves a driver line — engineered to express a recombinase or transcription regulator like Cre and Flpo (in rodents) or a Gal4 driver (in zebrafish) in a particular cell population — and an animal strain expressing a conditional opsin gene under the control of the relevant driver (Figure 3b). The F1 progeny of such a cross will express the opsin gene in all cells in which the driver protein is expressed, and will therefore be amenable to optogenetic manipulation simply by illuminating the targeted brain region. The approach is simple to implement, but one should consider potential caveats, including the presence of axons from neurons in other brain regions, which might be activated along with the cell bodies in the illuminated region. In mice, expression of ChR2 or eNpHR3.0 from the ROSA26 locus [79] can be quite weak and not universally sufficient to drive activity in every neuron subtype. Expression of opsin genes from the TIGER locus [80] showed stronger opsin expression and might therefore be useful for some target neuron populations. However, this approach requires generation and/or breeding of a dedicated animal strain for every targeted neuron population and thus lacks the versatility and cost-efficiency of viral vector-based approaches. Another potential confound is unintentional targeting in some driver lines (see for instance [81]), making the verification of driver lines advisable [82].

[H3] **Viral vector targeting**

Lentiviral or adeno-associated viral vectors (AAVs) can be engineered to encode optogenetic actuators and delivered either directly to the brain parenchyma or through systemic injection to target either specific brain regions or brain-wide populations, respectively. Targeting of genetically-identified neuronal populations is achieved either by using the tissue tropism of the virus serotype and a cell type-specific promoter or enhancer (Figure. 3c), or by injecting the viral vector into a transgenic recombinase-expressing animal strain (Figure 3d). Promoter-based viral vector targeting is attractive since it does not require the maintenance of a specific animal strain for every target neuron population, and can also be applied in non-genetic models. However, the limited viral payload size — particularly of AAVs — prohibits the use of most native promoters. The list of minimal promoter or enhancer sequences that have been validated to specifically express in defined neuron populations is quite restricted. However, this field is rapidly expanding[83,84] and is further diversified by synthetic approaches [85].

[H3] **Circuit-based viral vector targeting**

The most commonly used retrograde viral tracer is AAVretro[86], which can be taken up by presynaptic terminals and travel in retrograde to express at the soma of long-range projecting neurons (Figure 3e). The herpes simplex virus 1 (HSV1) and canine adenovirus 2 (CAV2) both have retrograde targeting abilities, but these are less readily available and have been shown to impair the health of targeted neurons, particularly over longer expression times of weeks to months [87].

[H3] **Systemic delivery of AAV-PHP capsids**

Targeting sparse brain-wide populations is beneficial for some experimental configurations. For example, structural imaging of dendritic spines in cortex or excitation of a randomly-selected sparse ensemble in a given brain region. For this purpose, AAV-PHP vectors have been engineered to cross the blood-brain barrier with high efficiency (Figure 3f). The AAV-PHP serotypes allow targeting of diverse central and peripheral nervous system neurons [88,89]. The same capsids can be used with Cre-dependent AAV expression plasmids to allow sparse brain-wide expression in a genetically-defined neuronal subtype. However, the efficiency of AAV-PHP serotypes in crossing of the blood brain barrier can vary in different mouse strains[90].

[H3] **Electroporation**

Concentrated DNA can also be injected into the cerebral ventricles followed by in utero electroporation [91-93], enabling the study of neural cell fate determination and migration or cortical layer specific expression.

[H2] Compartment-specific functions

The effective current resulting from a light-gated channel conductance can vary dramatically due to local ion concentration gradient differences. For neuroscience applications, this is particularly crucial for use of ACRs. At the somatic and dendritic compartments, this is an advantage, as they can be used for shunting inhibition. In contrast, ACRs can exert excitatory effects in axons and presynaptic terminals, in which the intracellular chloride concentration is higher (Box 1). Ion pumping rhodopsins on the other hand translocate the ion over the membrane in a predetermined direction, which can be an advantage due to the increased control of ion flux. However, the pumping-induced hyperpolarization and elevation in ion concentration can also have side effects, like the alkalinization of presynaptic boutons [94] or an artificial increase in intracellular chloride [42]. Similarly, the effects of G-protein coupled animal rhodopsins on neuronal activity strongly depend on the given second

messenger cascade in the local compartment. For instance, in the soma and dendrite, $G_{i/o}$ signaling can activate G protein-coupled inward rectifying potassium channels whereas in the presynaptic compartment the $G_{i/o}$ pathway mainly acts through inhibition of voltage gated calcium channels and cAMP signaling [54].

[H2] Optimizing expression and targeting

Beyond single channel conductance, one of the main factors determining maximal photocurrent is the number of functional opsin molecules in the membrane, which in turn depends on expression level, protein-folding efficacy, retinal binding affinity, membrane trafficking and protein turnover rate. The expression level of a transgene can be controlled via promoter strength and transgene copy number. The opsin-folding efficacy and protein stability was shown to depend on the availability of the chromophore retinal [95]. While retinal availability does not seem to be a limiting factor in mammalian tissues, it needs to be routinely supplemented in the food of invertebrate model systems and some cultured cell lines. In plants, the absence of retinal can be compensated for by its synthesis via expression of a bacterial ß-dioxygenase that facilitates rhodopsin expression. A common issue with unmodified opsin expression cassettes is aggregation of the synthetized protein in the endoplasmic reticulum (ER). To overcome this limitation, trafficking motifs involved in transport of membrane proteins along the secretory pathway to the cell surface were utilized to improve plasma membrane targeting (Supplementary Figure 4). The most widely-used trafficking motifs utilized were first described for the potassium channel $K_{ir}2.1$ — these motifs enhance ER export as well as Golgi-to-plasma membrane trafficking [96], resulting in higher plasma membrane localization and increased photocurrents in animal [97] as well as plant cells [98].

Further optimization of functional expression can be achieved by adjusting the linkers between the opsin and the often co-expressed fluorophore, mutating potential ubiquitination sites, and screening random mutations in the opsin coding sequence [99]. Beyond improved photocurrents, targeting an opsin to a selected subcellular compartment can be used to investigate the function of the chosen compartment, such as the mitochondria, synaptic vesicles, lysosomes or ER (Supplementary Figure 4), or to use the differential effects of ion channels discussed above. Somatic restriction has been successful in increasing the specificity of single-cell stimulation by reducing inadvertent modulation of nearby neurites [100-105], as well as in reducing ACR-mediated axonal excitation [24]. Somatic

restriction has the added effect of accelerating the effective photocurrent off-kinetics, due to the elimination of photocurrents arising from distal neurites in the illuminated tissue volume, as these are low-pass filtered while traveling along the neurite to the somatic compartment.

While targeting microbial rhodopsins to presynaptic vesicles is feasible[40], enrichment of rhodopsin abundance in the axonal plasma membrane has not been achieved. Cytosolic proteins can be enriched in the axon by mRNA shuttling motifs. However, local rhodopsin translation in the axon has not been successfully applied, potentially due to a lack of transmembrane protein synthesis in the vertebrate axon [106].

[H2] Light delivery techniques

Although the vast majority of advanced light targeting approaches have been developed with the specific applications of neuronal and cardiac optogenetics in mind, these methods are generalizable and are beginning to be applied to other systems[107]. Optogenetics is readily applicable to light-accessible preparations such as cultured cells, tissue slices, transparent organisms such as zebrafish larvae or to the cortical surface of the mammalian brain, allowing for extensive flexibility in light delivery. For whole circuit or brain region optogenetics, light needs to reach the target with sufficient irradiance to induce opsin activation. Ideally, light should be guided into the target structure with minimum damage to the tissue. In behaving animals, stimulation should also be conducted with minimal disruption to the measured behavior, limiting implantable weight and tether stiffness. Whole circuit/region optogenetic stimulation is typically carried out using a multimode optical fiber, guiding the light from the source to the target (Figure 4a-b). Optical fibers targeting a deep brain region can be permanently implanted by attaching a fiberoptic implant to the skull using dental cement. The dimensions of the fiber and its optical properties strongly influence the spatial profile of light reaching the brain. Most commonly, flat-cleaved optical fibers are used. However, the high radiant flux density necessary at the fiber tip to achieve a sufficient irradiance within the targeted volume, can lead to heat-induced changes in neuronal activity and behaviour [108,109]. It is therefore advisable to consider tissue heating when planning the experiment and to use opsin-free light stimulated controls. One approach to minimizing the irradiance required in optogenetic experiments is to maximize the operational light sensitivity of the opsin used (Supplementary Figure 3). Another factor is wavelength, as absorption is higher for shorter wavelengths and therefore the peak temperature increase is lower

400 for longer wavelengths at the same radiant flux density. Increased optical fiber diameter also reduces
401 the peak light power density. However, wider fibers also cause more tissue damage and have a higher
402 chance of illuminating blood vessels, which strongly absorb visible light and thus increase potential
403 heating-related artifacts. This tradeoff can be at least partially mitigated by the use of tapered optical
404 fibers (Figure 4b), which can be used to flexibly illuminate a large brain volume[110].
405 In these conventional optogenetic experiments, visible light is mostly delivered non-specifically to
406 large tissue regions and genetic targeting strategies are used to express the optogenetic actuator in
407 specific cell types. This approach has enabled tissue function to be mapped with unprecedented
408 anatomical and cell-type specificity. However, widefield illumination synchronously activates or
409 silences entire populations of all opsin-expressing cells, which does not replicate the physiological
410 case: adjacent cells belonging to genetically defined classes have been observed to exhibit divergent
411 activity patterns. To investigate complex population activity patterns, whole-region optogenetics is
412 insufficient. DMD coupled to single-photon excitation have enabled single and multi-target excitation
413 in head-restrained and freely-moving animals and found in situ applications in control of excitation
414 waves underlying cardiac arrythmias[111,112113,114]. However, the use of visible light has limited these
415 approaches to superficial brain layers or low scattering samples. Recent developments in opsin
416 engineering, optical microscopy and multiphoton laser source development have given rise to circuit
417 optogenetics[115], which allows modulation of neuronal activity deep in scattering tissue with single-
418 spike precision and single-cell resolution (Figure 4c-e). Specifically, combining variants with
419 enhanced kinetics [30 116-118], higher conductance [116,118,119] or shifted absorption peaks [30,119,120] with
420 optimized targeting and expression strategies [101-104], enable neuronal control with single-cell, single-
421 spike precision at millisecond temporal resolution and the generation of action potential (Ap) trains
422 with high (50–100 Hz) spiking rates [121,122]. In parallel, advanced optical techniques, based on two-
423 photon (2P) excitation (Box 2) have been developed to precisely guide light through tissue. The small
424 single-channel conductance of commonly used optogenetic actuators such as ChR2 (40–90 fS)[123], and
425 the limited number of channels or pumps recruited within a conventional 2P focal volume, mean that
426 it is generally necessary to use spiral scanning or parallel light shaping using computer generated
427 holography or the generalized phase contrast method (Supplementary Figure 5) combined with
428 temporal focusing (Supplementary Figure 6) [14] to increase the portion of excited membrane [124,125] and
429 to sufficiently depolarize a neuron to firing threshold or effectively silence it. Holographic light
430 multiplexing with spiral scanning [126] or ad hoc spatiotemporal shaping approaches (Supplementary

Figure 7) have been used to generate patterned illumination at multiple axially distinct planes [116,127,128]. Multiplexing divides the available laser power between targets and thus requires powerful lasers. Due to the higher peak photon density, amplified low-repetition rate (200 kHz – 10 MHz) fiber lasers enable higher rates of 2P absorption compared to titanium:sapphire oscillators (at the same average power) and can therefore be used to reduce the necessary power to generate physiological signals [129]. Additionally, these sources deliver tens of Watts of power, facilitating the simultaneous photostimulation of hundreds of cells throughout mm^3 volumes. The combination of these technologies has recently led to the first demonstrations of multi-target neural circuit manipulation [104,118,130].

The ability to control neuronal activity with single-cell precision and millisecond temporal resolution allows to functionally probe neuronal networks beyond the resolution of synchronous modulation of entire networks or genetically defined network components. For instance, using temporally precise single-cell excitation in visual cortex and olfactory bulb, the minimal number of co-activated cortical neurons necessary for visual perception [131] and the dependence of olfactory perceptual detection on both the number of activated neurons and their relative spiking latency was characterized [132]. The requirement of high numerical aperture objectives has limited 2P-optogenetics to circuits in superficial (≤ 500 μm) cortical areas of mouse brain, transparent zebrafish larvae [133] or in-vitro applications. Micro-endoscopes are small optical probes that can be inserted into living tissues, and represent a promising solution to extend optical brain manipulation to deeper brain structures both in combination with holographic spiral scanning [134] or multi-temporally focused light shaping approaches [135]. Three-photon (3P) optogenetics, which relies on longer wavelengths and exhibits a cubic dependence of excitation efficiency on excitation power, could potentially be used to stimulate neuronal circuits in deeper brain regions (600 μm – 1 mm) with single-cell resolution. However, to date, 3P photostimulation has only been demonstrated in vitro [136].

[H1] Results

[H2] Output analysis

When designing optogenetic experiments, care should be taken to verify the impact of the optogenetic manipulation on the targeted cells. This can be achieved in a number of ways, including

electrophysiological recordings in vitro or in vivo, optical recordings with genetically-encoded sensors, immediate early gene labeling and noninvasive imaging modalities. Below we outline the major techniques used in such experiments, and the considerations that should be taken into account when designing and performing such experiments.

[H3] Electrophysiological recordings

To interpret the results of optogenetic manipulations, it is often necessary to determine the extent of optogenetic tool expression and its physiological effects on the targeted neurons. In the case of light gated ion channels or pumps, recording the electrophysiological changes induced by the optogenetic manipulation is the most direct way to characterize light-mediated effects (Figure 5a-c). As these effects can vary greatly between cell types, brain regions and even viral serotypes [137], it is crucial to validate the optogenetic effector in every new experimental system before proceeding to behavioral or other functional readouts. To describe effects on the level of spike rates and timing, whole-cell recordings are often not necessary. Instead, extracellular recordings are often used (Figure 5d-f), given their higher throughput and minimal crosstalk with light delivery (see[138] for discussion of light-induced electrical artifacts). However, higher frequency spiking activity does not necessarily indicate increased synaptic transmission from the stimulated neurons[137]. Synaptic depression and depletion of neurotransmitter release can lead to erroneous interpretation and should be taken into account when performing optogenetic excitation experiments, particularly with neuromodulatory and neuropeptide-releasing neuronal populations.

[H3] Optical recordings

Fluorescent reporters are another common method for monitoring the effects of optogenetic manipulations. These techniques enable recording from the same cells over several recording sessions and the concurrent recording of high numbers of cells. However, given that optogenetics itself relies on light delivery, fluorescent reporters can be efficiently integrated only if a spectral or light power separation can be achieved to minimize the crosstalk between the recording and manipulation modalities (Supplementary Figure 2). Additionally, when combining red-shifted Ca^{2+} indicators with

optogenetic actuators, extra care must be taken, as these can show blue-light-activated photoswitching behavior that can resemble Ca^{2+} activity in their amplitude and kinetics [139].

While genetically encoded calcium sensors continue to be the state of the art in terms of optical activity readout, voltage indicators are gradually reaching a level of maturity that could allow for wider adoption by the field [140]. Novel fluorescent sensors for neurotransmitters, neuromodulators and other small molecules are continuously developed[141-143]. Another approach to read out gross neuronal firing rate changes is to characterize the expression of immediate early genes **[G]**, for instance via immunohistochemistry on the protein level [144] or on the mRNA level using quantitative PCR, in-situ hybridization or single cell RNA sequencing [145]. Immediate early gene expression can be used to determine the relationship between the modulation of specific neuronal populations and global brain activity [146]. However, the temporal precision of this approach is limited to the average neuronal activity over minutes to hours and, unless combined with targeted recombination approaches [147], only a single manipulation can be characterized per animal.

Although channelrhodopsin variants with peak single-photon (1P) excitation wavelengths spanning the visible region of the electromagnetic spectrum have been engineered [26], performing crosstalk-free, multi-colour 2P experiments is not trivial. Ideally, spectrally orthogonal channelrhodopsins and activity reporters would be chosen, but, unfortunately, the 2P action spectra of commonly used opsins are extremely broad (Supplementary Figure 8) [26]. As previously introduced, opsins with red-shifted action spectra exhibit persistent activation in the blue range, which coincide with wavelengths used for 2P imaging of commonly used activity reporters (920 – 980 nm). One approach to reduce crosstalk is to use opsins with fast kinetics. Although this approach does not eliminate sub-threshold network perturbation, the (relatively) fast repolarization of neurons expressing channelrhodopsins with fast off-kinetics means they are unlikely to fire action potentials due to excitation by the imaging laser during scanning. Successful employment of this method requires careful titration of imaging parameters, including imaging power, frame rate and field of view. This is an interim approach until high efficiency blue-shifted opsins, red-shifted activity indicators and amplified lasers in the appropriate spectral range become more widely available.

[H3] Alternative recording modalities

Electrophysiological and optical recording modalities both suffer from potential interactions with the light required to excite optogenetic actuators. The hemodynamic response **[G]** is an alternative physiological response to neural activity which can be exploited to report the impact of optogenetic modulation. For superficial brain areas such as the cortex, the hemodynamic response can be measured via intrinsic imaging [148,149], while functional magnetic resonance imaging[150] can be utilized to record brain-wide hemodynamics. Although the noninvasive nature and the ability to measure the hemodynamic response throughout the entire brain are major advantages, the main drawbacks are that the temporal resolution of this approach is fundamentally limited by the specificity and kinetics of the hemodynamic response itself and the limited spatial resolution of neurovascular coupling [151]. Heating should also be taken into account here as it can directly impact the hemodynamic response [152]. Functional ultrasound imaging is a rapidly developing technology which could be used to perform brain-wide detection of neural activity triggered by localized optogenetic stimulation. Although this method still relies on changes in neurovascular blood volume changes, it can be performed at a fraction of the cost of functional MRI recordings and is rapidly advancing to allow better spatio-temporal resolution and portability [153].

[H2] Linking neural to behavioral readouts

The exquisite spatial and temporal control of genetically defined cells with optogenetics are attractive features for experiments aiming at establishing links with causality between neural activity and behavior. The growing understanding of neuronal coding has also led to a nuanced understanding of the limits of interpretability of such experiments. However, when appropriately designed and controlled, optogenetic experiments can provide important information on how neural circuits drive behavioral processes.

Choosing the locus of intervention may be instructed by previous literature, lesion experiments and behavioral pharmacology. For example, we know that silencing the motor cortex with compounds like muscimol or baclofen causes motor impairment while optogenetic stimulation elicits muscle contraction[154]. While gain of function experiments may be a starting point, cell type-specific optogenetic inhibition of genetically-defined neurons in the motor cortex would provide a more complex picture, better dissociating physiological motor response from an artificial perturbation[155]. Another way to determine the brain region and cell types of interest is the use of activity markers such as the immediate early genes c-*Fos* or *Arc*. Finally, technological advances in wide-field optical

551 monitoring of intracellular calcium may allow to visualize the activity of large cortical areas[151,156] and
552 selectively silence defined cortical regions transcranially[157]. Alternatively, high density electrical
553 recordings[158,159]can elucidate the activity of many neurons in deeper structures. This allows the
554 experimenter to identify circuits with activity patterns that may be relevant to the behavior to be
555 studied.

556 Observational experiments should be implemented to characterize the functional properties of
557 the cell population to be modulated (Figure 6). This may be achieved using electrophysiology in vivo
558 — for example, by tetrode recordings of photo-tagged neurons [160] or genetically encoded calcium
559 sensor imaging[161]. The choice of the optogenetic intervention should ideally be instructed by these
560 observational investigations and match the dynamic range of the activity observed. Additional
561 selectivity can be achieved by aiming at axon terminals rather than cell bodies. Effectors aiming at
562 hyperpolarizing terminals or creating shunting inhibition may not always be efficient or at times even
563 perturb para-membranous ion concentrations such that the effect is difficult to predict[39]. With the
564 advent of $G_{i/o}$-coupled effectors[53,54], presynaptic inhibition is more straightforward, but it remains
565 good practice to validate the efficacy of inhibition, as well as its spatial selectivity, particularly with
566 the highly light-sensitive effectors. It is particularly important to take into account the firing frequency
567 of the cells under investigation as presynaptic inhibition is potentially less efficacious at higher firing
568 rates.

569 There are two distinct approaches for optogenetic manipulations, one with an acute effect, the
570 other with long-lasting effects. Acute manipulations require behavioral observations in real time.
571 Ideally, a small set of optogenetic trials should be randomly interleaved with control trials. This allows
572 us to assess not only the acute effects on optogenetic trials, but also to determine if there are longer-
573 lasting changes to the subsequent control trials. Such laser on-off protocols can be used to control for
574 adaptive behavioral changes throughout a given session. However, often the particular structure of
575 the behavioral paradigm does not allow for hundreds of trials. The timing of the optogenetic
576 stimulation or inhibition should therefore occur in a behaviorally defined window, and be only as long
577 as is strictly necessary.

578 Long-term observation is appropriate when optogenetic interventions exploit synaptic
579 plasticity mechanisms. For example, synaptic potentiation typically is achieved by high stimulation
580 frequency, while depression requires sustained low frequency stimulation. Optogenetic synaptic

plasticity protocols are particularly suited to study learned and adaptive behavior. The goal of long-term observation experiments is to induce synaptic plasticity at identified synapses and observe the effect on behavior at a later time point when optogenetic stimulation is no longer active. For example, low-frequency optogenetic stimulation can restore baseline transmission in cortico-accumbal synapses that have been potentiated by cocaine exposure [162]. Similarly, daily optogenetic stimulation of orbitofrontal to dorsal striatum axons for 10 minutes triggered long-term changes in synaptic strength and inhibited compulsion [163].

[H1] Applications

The vast majority of applications of optogenetics have involved neuroscience and brain research. Many of the general principles and approaches of optogenetics can be extended to other organs, particularly to those with excitable cells — like skeletal muscle, heart, retina and gut — as well as to microorganisms and plants. These newer applications often present unique challenges and opportunities. Below, we illustrate some of these aspects with three select examples from visual, cardiac and plant applications.

[H2] Vision restoration

Retinal degenerative diseases, such as retinitis pigmentosa (RP) and age-related macular degeneration (AMD), result in the loss of rod and cone photoreceptor cells, leading to partial or complete blindness [164,165]. Rendering inner retinal neurons responsive to light is one of the most obvious medical applications for optogenetics (Figure 7A). The first proof-of-concept study involved the ubiquitous expression of ChR2 in retinal ganglion cells in retinal degenerated mice[166]. The approach since then has been reported by numerous studies using different optogenetic tools, retinal cell targeting strategies and animal models (Supplementary Table 1).

Multiple clinical trials using ChRs for treating RP-related blindness have been initiated since 2015, with encouraging results (Supplementary Table 2). Recently, the first published case study reported the partial restoration of vision (in the form of perceiving, locating and counting objects) in a blind patient with RP [167]. Positive preliminary results have also been reported in other clinical trials (Supplementary Table 2). However, further efforts will be required to improve the outcome of optogenetic vision

609 restoration, including the development of effective optogenetic tools and treatment strategies, and the
610 improvement of gene delivery efficiency.

611 [H3] Optogenetic tools

612 ChRs have been the more commonly used optogenetic tools for vision restoration in animal models
613 and the ones used so far in clinical trials. Two main issues should be considered when choosing an
614 optogenetic tool for vision restoration. The first is the tool's expression efficiency and long-term
615 safety in mammalian neurons; problems with the expression of an optogenetic tool are difficult to
616 correct and usually result in cell toxicity in the long-term. The second issue is the low operational
617 light-sensitivity of ChR-expressing retinal neurons in general caused by the small unitary conductance
618 and substantial inactivation. The requirement of high light-intensity to activate the ChR-expressing
619 retinal neurons constrains this application and also raises concerns regarding tissue photochemical
620 damage, especially for short-wavelength sensitive ChRs. One solution to mitigate the potential
621 photochemical damage is to use red-shifted ChRs, such as Chrimson, since the threshold of light
622 intensity causing tissue photochemical damage is shifted to higher light-intensities for longer
623 wavelengths[168-170]. Another solution is to improve the light sensitivity of a ChR expressing cell by
624 slowing its closing kinetics or off-rate with molecular engineering [171] (Supplementary Figures 1 and 2)
625 combined with genome mining for more potent ChRs [30]. This strategy has been recently used to further
626 optimize the more effective ChR variant CoChR. Functional vision is restored with improved CoChR
627 mutants under ambient light conditions in a blind mouse model [172]. A third solution is to use GPCRs,
628 including animal opsins (for example, rhodopsin and cone opsins) [173-175] or engineering of optoGPCR
629 chimeras [176], taking advantage of their high light sensitivity due to intracellular signal amplification.
630 Further studies will need to evaluate the most effective optogenetic tools or develop better ones for
631 this application.

632 [H3] Gene delivery

633 AAV vectors are the current choice for transgene delivery in the retina both in animal studies and in clinical
634 trials [177]. Intravitreal injection is a preferred route of viral vector administration due to its safe
635 operation and ability to achieve widespread delivery to the retina. However, in non-human primates
636 and in humans, virus transduction was mainly conferred to a narrow region surrounding the fovea or
637 parafoveal region [178,179], due to the barrier of a thick limiting membrane in the retinal surface of

primates [22], which is one of the major factors limiting the outcome of AAV-mediated optogenetic therapy. Further development of more efficient gene delivery vehicles or techniques is required.

[H3] Retinal cell targeting

Most animal studies and clinical trials have employed ubiquitous promoters to express depolarizing ChRs in retinal ganglion cells. However, unlike the normal visual processing features in the retina including the segregation of ON and OFF signal pathways and the presence of antagonistic center-surround receptive fields (Figure 7Aa), this treatment strategy converts all retinal ganglion cells to ON cells (Figure. 7Ab). Although useful vision could still be generated as demonstrated in animal studies and reported from clinical trials, it is commonly believed that restoration of vision to mimic the intrinsic visual processing features in the retina would result in a better outcome. To this end, one strategy is to target an optogenetic tool to distal retinal neurons. Targeting a depolarizing ChR to ON bipolar cells using the mGluR6 promoter has been the most commonly employed strategy (Figure 7Ac). Due to the unique rod pathway in the mammalian retina, this could lead to ON and OFF responses at the level of retinal ganglion cells [180-183], and possibly center-surround receptive fields. Targeting surviving cone photoreceptors with a hyperpolarizing optogenetic tool, such as eNpHR, has also been reported [184]. As a limitation for this strategy, the distal retinal neurons are more susceptible to severe retinal deterioration or remodeling than retinal ganglion cells after the death of photoreceptors[185]. Multiple treatment strategies will need to be developed for treating patients with different retinal degenerative conditions.

[H2] Cardiac research

The key benefits for clinical translation are sought in more versatile optogenetic pacing or suppression of wave propagation during arrhythmias, compared to currently used cardiac devices like pacemakers and cardioverter/defibrillators (Figure 7B) [186-193]. Strategies for rhythm control enabled by optogenetic actuators aim to lower the energy needed to power cardiac devices and extend battery life by delivering longer lower-energy light pulses — electrical pulse duration is limited due to electrochemical toxicity via Faraday effects. Optogenetic actuators also eliminate discomfort and pain during classic cardioversion/defibrillation for better quality of life by using cell-specific genetic targeting to engage the fast conduction system [190,194] or to specifically target myocytes and avoid unintended contractions of thoracic skeletal muscle, diaphragm and vocal cords like pain-inducing electrical defibrillation [195]. Computational modeling of the action of optogenetic tools in the heart

668 helps to explore strategies for control of arrhythmias, both with excitatory/depolarizing opsins and
669 with inhibitory/hyperpolarizing opsins [113,189,190,196,197]. Longer-term in vivo clinical applications face
670 the challenges of genetic modification of the hard-to-access cardiac muscle, potential immune
671 responses and realizing embedded miniaturized light control devices that are reliable and safe [193].
672 Light penetration in the haemoglobin-rich heart muscle requires operation in the near-infrared and
673 opsins excitable within that range, along with stabilization techniques to counter mechanical
674 contractions. The atria are thinner (human atria are < 5mm) and present an easier target, along with
675 more accessible autonomic nerves, such as the vagus nerve [198].

676 AAV9 is the most efficient AAV serotype for targeting the ventricular myocytes in vivo when
677 using an ubiquitous or a specific promoter, such as Myh6 [199]. The heart atria can be targeted
678 optogenetically using the NPPA promoter and local viral gene delivery [192]. Cre-Lox transgenic mouse
679 models with suitable promoters have been used to transform the fast conduction system cells
680 (Cx40)[194], sympathetic neurons (tyrosine hydroxylase, TH) [200], and parasympathetic neurons (choline
681 acetyltransferase, ChAT) [198,201] (Figure 7Ba). To translate the approaches from rodents to larger
682 animals, more work is needed in finding minimally-invasive ways of transgene delivery to the heart
683 and in minimizing immune responses. Previous clinical trials on gene therapy for cardiac disorders
684 found that a large portion of the patients had antibodies against the viral vectors used, thus reducing
685 the efficacy of the therapy[202]. Most of the published studies have used ChR2-H134R as excitatory
686 opsin. In general, more efficient and fast inhibitory opsins are desirable for arrhythmia control
687 applications. There may also be a niche for step-function-like depolarizing [G] opsins that have fast
688 recovery from inactivation as clamping tools in arrhythmia management. Bidirectional closed-loop
689 control could make an all-optical approach, named optical clamp [G] at the whole organ level a reality.
690 However, this will require spectral compatibility to accommodate not only for an excitatory and an
691 inhibitory opsin, but also for the optical readout of a voltage indicator.

692 Overall, clinical applications of optogenetics in the heart face many challenges compared to
693 the more accessible, immune-privileged applications to the eye that have seen translational advances.
694 Considering the potential impact for control of arrhythmias, efforts should continue to improve the
695 genetic targeting by more specific promoters, safer viral vectors, longer-wavelength opsins for better
696 penetration and miniaturized distributed light sources. Basic science experiments with optogenetic
697 tools provide invaluable insights for improvement of current cardiac devices and may yield new

strategies for arrhythmia control [112,114,193,203,204]. These new strategies take advantage of the ability to produce complex space-time control patterns by light (unlike discrete signals from electrode arrays) to steer waves of excitation towards non-arrhythmic behavior at very low energy. Optogenetics-empowered high-throughput systems can more immediately improve cardiotoxicity testing and drug development. All-optical cardiac electrophysiology, which combines optogenetic actuators and optical/optogenetic sensors [205-207], offers immediate adoption and translation (Figure 7Bc). Cardiotoxicity testing is crucial in the development of any new pharmaceutical, and high-throughput optogenetic methods with patient-derived cells represent impactful technology for personalized medicine [208,209]. Optogenetic techniques using hyperpolarizing opsins like ArchT have been used to dynamically alter the action potential characteristics of induced pluripotent stem-cell-derived cardiomyocytes (iPSC-CMs) towards a more mature phenotype to better predict drug responses [210]. The maturity of tissue-engineered constructs of such patient derived iPSC-CMs can be improved through chronic optogenetic pacing [209] towards new regenerative solutions for the heart (Supplementary Figure 9).

[H2] Plants

A large set of photoreceptors that control phototropism, diurnal rhythms and photomorphogenesis play fundamental roles in plant growth and development. Blue-light absorbing phototropins and cryptochromes or red/far-red light absorbing phytochromes are found in almost all plant tissues (Figure 7Ca). Therefore, when using optogenetics tools in plants, the light regime **[G]** used needs to be considered. The light required for plant growth will activate optogenetic tools when light of the entire visible spectrum is used; this can be avoided by combining a blue light-regulated transcriptional repressor with a red light-triggered switch [211], allowing plants to grow at ambient white light. The use of flavoprotein-based optogenetic tools in plants has been described in detail recently [212,213]. Based on the light-oxygen-voltage (LOV) domain, a synthetic light-gated K^+ channel with considerable dark activity, called BLINK1, was recently expressed in Arabidopsis guard cells for control of stomatal behavior [214]. The mechanism of BLINK1 light activation that clamps the membrane potential to E_K and facilitates stomatal opening and closing in the same way, remains to be clarified. A rather simple but valuable technique to avoid non-specific activation of rhodopsin-based optogenetic tools is to grow plants exclusively in red light [98,215]. Both chlorophyll a and chlorophyll b absorb red light (Figure

728 7Ca), and tobacco plants exclusively grown in red-light are hardly distinguishable from those grown
729 in white light [98]. Green light is the least absorbed wavelength by endogenous plant photoreceptors,
730 therefore, green light allows for optogenetic manipulation with only minimal crosstalk [98] (Figure
731 7Ca), especially with GtACR1.

732 Rhodopsin-based plant optogenetic approaches are still in their infancy compared to their
733 long-standing use in animals. The combination of ubiquitous rhodopsin expression with global or
734 local light-emitting diodes (LED) or laser light applications have been used in plants[98,215-217].
735 However, cell type-specific expression with global green light exposure certainly bears great
736 potential, when combined with red light growth conditions. Use of the LeLAT52 pollen-specific
737 promoter[218] allows plants to be grown in white light under greenhouse conditions for optogenetics-
738 inspired research on pollen tubes [98]. For local rhodopsin stimulation at the single-cell level, fiber-
739 optics or laser light pulses have been successfully applied[98,217]. The Fluorescence Recovery After
740 Photobleaching (FRAP) module of conventional laser scanning microscopes allows local optogenetic
741 stimulation of plant cells when using rhodopsins, like GtACR1, with activation kinetics in the lower
742 ms range[98].

743 To perform plant optogenetics with rhodopsins, retinal can be added externally [215]
744 (Supplementary Figure 10 a-c), or plants can be empowered to produce retinal by expressing a ß-
745 dioxygenase from a marine bacterium targeted to the chloroplasts to synthesize retinal from
746 carotenoids efficiently [98] (Supplementary Figure 10 d-f). In contrast to animal cells, the plant cell
747 extracellular medium is low in ions and mostly moderately acidic, which may result in different
748 electrical responses in plant and animal cells using the same rhodopsin (Supplementary Figure 11).
749 Activation of ACRs in the soma of neurons leads to membrane hyperpolarization [219], while
750 depolarization occurs in plant cells [98] due to the outward-directed anion gradient. When expressed in
751 leaves or pollen tubes, activation of GtACR1 by green light (530 nm) resulted in membrane
752 depolarization by about 60–100 mV within milliseconds[98]. Local GtACR1 activation on one side of
753 the dome of apically growing pollen tubes has been used to demonstrate the involvement of an anion
754 efflux in polar growth [98] (Supplementary Fig. 10 e, f), supporting earlier studies on the role of anion
755 transport in polar growth [220,221]. In guard cells, native anion channel activity can be mimicked when
756 GtACR1 is triggered by a series of light pulses (Figure 7Cc-f), demonstrating that anion channel
757 driven depolarization is sufficient to close stomata [217]. Although plants do not have neuronal-like
758 networks, voltage changes in the form of depolarization waves are transmitted between leaves or even

between different organs [222-224]. The role of these long-range electrical signals can now be investigated with the help of GtACR1. Through GtACR1 induced anion efflux, depolarizations of any shape and intensity can be optogenetically generated to mimic the voltage changes observed in plants such as variation potentials, system potentials or action potentials[225-227].

A wide-range of processes in plants are induced by changes in cytoplasmic Ca^{2+} and H^+ levels [245,246]. For both ions, there is a strong inward gradient, in contrast to animal cells, where there are minimal differences in intracellular and extracellular pH (Supplementary Figure 11). The slow cycling ChR2 variant XXL with high proton conductance[228] is excellent to impose light-induced pH changes, and has already been used to feed the P-type plasma membrane H^+ pump with substrate and study its voltage dependence [215](Supplementary Figure 10 b, c). The resting potential of plants is negative with respect to E_K (-120 to -180 mV) due to the voltage dependent activity of P-type plasma membrane H^+ pumps. The latter hyperpolarize the membrane and acidify the cell wall space [229]. This voltage deflection is used by the plant to open hyperpolarization active Shaker type K^+ channels [230] and electrophoretically move K^+ ions into the cell [231]. The combined driving proton-motive-force (PMF) of the electrical gradient and that of the H^+ is used by solute transporters using protons as co-substrate. The plant optogenetics toolbox therefore needs to be complemented by light-driven H^+ pumps such as Arch3. Great potential for the study of Ca^{2+} signaling is the ChR2 variant XXM with increased Ca^{2+} conductivity and medium open state lifetime [232]. Combined with electrophysiology and Ca^{2+} imaging, the molecular mechanisms for long-distance Ca^{2+} signaling could be resolved. Ca^{2+} signatures can represent either single events or rhythmically recurring signals. Whether and how different Ca^{2+} signatures control specific processes in plants is still largely unexplored. In the future, Ca^{2+}-permeable ChRs could be used to elicit defined Ca^{2+} signatures.

[H1] Reproducibility and data deposition

[H2] Reproducibility of optogenetic tools

Reproducibility in optogenetics experiments depends on the consistency of the tools used, the organism/cell type, genetic transformation procedures and light delivery. Adherence to minimum reporting standards for all relevant parameters of an experiment can help to increase reproducibility.

Optogenetic actuators are used in a diverse range of organisms, tissues and cell types. Because of differences in codon usage between the original host and the organisms in which the tools are applied, it is common to codon-optimize the coding sequence to facilitate translation in these heterologous systems. New codon-optimized sequences should be tested for expression, membrane targeting and function before applying these novel constructs in optogenetic experiments. The sequences of codon-optimized constructs should be appropriately reported in publications to allow reproduction of findings in other laboratories. However, even with codon-optimization or adding traffic motifs, the intracellular aggregation of many optogenetic actuators can still pose a problem for their applicability, particularly for translational applications. A thorough evaluation in targeted organism/cell type is needed because the intracellular aggregation not only reduces expression efficacy but also affects cell health or causes cell death.

Viral vectors are a popular gene-delivery system for optogenetic tools. The quality of viral vectors, purity and viral titer can profoundly affect the transduction efficiency and experiment outcome. The quality of viral vectors produced by different laboratories, centralized viral vector cores and companies can vary widely. Variation can even occur from batch to batch produced at the same facility. Therefore, even when produced by centralized viral vector cores, service centers and major labs, viral vector preparations can vary in quality and efficiency. To minimize the variation, standardized purification and titration methods should be used. Each batch needs to be verified before scaling up experiments in order to obtain reproducible results.

[H2] Reproducibility of opsin expression

Evaluation of the viral titer is needed to optimize viral vector spread and expression level, and to minimize overexpression-mediated off-target effects. Many opsin viral vectors were designed to co-express a fluorophore. Standard histological methods can be used to visualize the strength and spatial extent of viral vector expression. Characterizing viral expression for every experimental animal can increase interpretability by correlating the variability in behavioral effect to the variability in expression area and, for instance, optical fiber placement. Even when an experiment is planned based on published work, the experimental design should be validated in each new experiment due to the potential variability of viral vector batches, optical hardware and mouse strain. When presenting results obtained using viral vectors, the source of the viral vector, its purification and titration methods, and the duration of expression should be reported.

Viral vector expression can impact cell health or change the electrophysiological properties of the targeted neurons. It is therefore necessary to include a control group injected with a titer-matched virus that expresses a control transgene. Researchers often use a virus encoding the same fluorophore that is co-expressed with the opsin. This control group can be used to evaluate direct effects of the virus injection surgery and potential phototoxic or heating effects due to the light delivery paradigm. Strong opsin expression has been reported to affect cell physiology [233]. It is therefore advisable to include an opsin expressing group where no light is applied. Where the experiment allows for multiple repeats of the same manipulation, light and no light conditions can be tested in the same group, which presents a within-animal control.

Transgenic animals for optogenetics research should be genotyped continuously to confirm suitability for the experiments. For in vivo optogenetics with viral delivery, even when using the same tools in the same organism type, variations in responses may be due to variations in the immune response of the subjects (animals or humans) to the viral capsid, or the cargo (opsin and/or fluorescent reporter). To obtain reproducible data with viral delivery, testing for neutralizing antibodies can be implemented [234]. Appropriate control groups, immunohistochemistry and histology should be done routinely in animal experiments to demonstrate consistency of the optogenetic transformation.

[H2] Reproducibility of light delivery

Activation of optogenetic tools depends on the photon irradiance or photon exposure in case of short flashes and the spectral profile of the delivered light. The spectral profile should be reported by listing the light source, all filters and optical components used in the experiments. Insufficient irradiance may lead to failure to engage the optogenetic tools and therefore failure to reproduce the phenotypic changes; excessive irradiance may lead to adverse thermal effects and photoreceptor bleaching that also affect reproducibility. For single-photon excitation, the spatial pattern of the delivered light is variable and highly depends on the positioning of the light source and the tissue properties. While total power is trivial to report, the normalized values of irradiance are influenced by the uncertainties of area estimation and the non-uniform spatial profile of light delivery. At a minimum, effort should be made to measure and report irradiance at the tissue point-of-entry. Whenever possible, light-tissue interactions can be simulated [235] to yield relevant estimates of irradiance at points of interest.

Under optimal conditions, two photon optogenetics is capable of stimulating individual neurons within a circuit with single spike and single cell resolution. Irrespective of the light sculpting method used (spiral scanning or parallel illumination), one must keep in mind that the effective spatiotemporal resolution of optogenetic stimulation depends on several factors, including the functional expression level of the opsin, the targeting specificity, and the photon density required for sufficient actuation. Once a reliable and reproducible experimental preparation has been established, and the average incident powers required identified, the physiological resolution should be measured experimentally rather than drawing any conclusions about the confinement of actuation based on the optical resolution of the light targeting method.

[H2] Data and metadata sharing

The data type and format from optogenetics experiments can be extremely diverse. Outputs may include spectra, ion channel recordings, functional recordings of responses by different measurement technologies, images of altered responses and behavioral analysis, among others. For each sub-field where optogenetics is deployed, minimum standards of reporting and guidance of data sharing will help determine best practices. In general, specifics of the instruments used, the acquisition and the analysis software need to be included. Github, figshare and other general repositories for data and analysis tools can be used to increase reproducibility.

[H1] Limitations and optimizations

[H2] Tissue heating and photodamage

[H3] Single-photon optogenetics

Optogenetic experiments based on illumination with visible light excitation (450–630 nm) typically use optical fibers coupled to lasers or high-power LED for large (~mm^3) field illumination, relatively long (0.5 – 60 s) exposure times and excitation powers on the order of milliwatts (0.5–20 mW). Under these conditions, the main cause for concern with respect to photodamage is heating due to light absorption. This has been investigated both theoretically, using Monte Carlo with finite-difference time-domain simulations[108] or the finite element method [236], and experimentally using thermocouples[108,236], infrared cameras [237] or electrophysiological recordings [238]. Depending on the precise stimulation protocol used, these experimental and theoretical studies report a wavelength and

power density dependent temperature increase between 0.3–6 K throughout the volume of illuminated tissue [237] [108]. Temperature variations on the order of only 2 K can affect ion channel kinetics and conductance [239], synaptic transmission [240] and neuronal firing rate [108], and lead to a bias in turning behavior across various brain regions[238]. Importantly, changes in temperature can induce physiological changes in the absence of detectable changes in behavior [241]. It is extremely important to carefully design optogenetic experiments to minimize photon exposure and absorption, for instance by using short illumination duty cycles [237] and opsins with long open state lifetimes and red-shifted absorption peaks [30,104,242]. Simulations [108,237,243,244] can be used to guide experimental design, but, since the effects of heating vary between cell types and brain regions, opsin-negative controls should always be performed.

[H3] Multiphoton optogenetics

Generating sufficient rates of multi-photon excitation requires the use of pulsed lasers with high peak energies, but since typical optogenetic stimulation protocols irradiate cells on millisecond timescales, the temperature rises induced by single-cell multi-photon photostimulation are of the order of 10^{-1} K [244]. Much larger temperature rises are induced during multi-target excitation due to the diffusion of heat from each target into the surrounding tissue. The resultant temperature increase occurs over hundreds of milliseconds and can approach or even exceed the 2 K threshold for thermal damage [244]. This effect can be mitigated by ensuring that the separation between adjacent targets is larger than the thermal diffusion length.

The risk of non-linear photodamage increases with peak fluence and could be a dominant source of photodamage in the case of spiral scanning which typically requires higher photon density than parallel illumination. Non-linear photodamage can be reduced by increasing the repetition rate of the pulsed laser source although this will increase photo induced temperature rises [244]. In all-optical experiments which combine 2P optogenetics with 2P imaging, the possibility of thermal or nonlinear damage induced by the imaging laser should also be considered[243].

[H2] Interpreting optogenetic experiments

903 Light delivery schemes based on single-photon excitation are not generally capable of recapitulating
904 physiological activity patterns. In most optogenetic gain and loss of function experiments, a set of
905 cells is activated or silenced, and the effects of this manipulation are subsequently characterized by
906 functional or behavioral readouts to probe causal dependencies. Light-delivery via an optic fiber can
907 be precisely controlled in terms of output power and temporal pattern to influence neuronal functions
908 like spike rate and spike pattern and may be restricted to specific short behavioral epochs. However,
909 such optogenetic manipulations typically lead to highly synchronous activity patterns, and might drive
910 the circuits to states that are outside of their physiological activity range, potentially confounding any
911 causal inference regarding the natural functions of the circuit [272]. One major current effort aimed at
912 overcoming these constraints is the development of tools for evoking naturalistic network activity
913 patterns. Such manipulations would enable causal inference of the effects of an activity pattern on a
914 given behavior.

915 Non-physiological activity patterns can occur at the single-cell level as well as at the broader
916 circuit scale [245,246]. On the single-cell level, ion pump-mediated hyperpolarization for instance can
917 lead to rebound excitation upon inhibition release [247] or to supra-physiological ion concentrations [42,94].
918 High-frequency light pulse trains or constant illumination of an excitatory pyramidal neuron
919 expressing a CCR can, for instance, lead to depolarization block, effectively reducing rather than
920 increasing its firing rate [248]. Whether such rebound excitation or depolarization block occurs and to
921 what extent is hard to predict, as it depends on many experiment-specific parameters which can greatly
922 vary between laboratories. While axonal stimulation can be used to effectively isolate the activity of
923 an anatomically-defined projection pathway, optogenetic stimulation of axons can cause antidromic
924 activation **[G]** of both neuronal cell bodies as well as collaterals to other brain regions, leading to
925 reduced specificity which should be taken into account.

926 At the circuit level, particularly when a large portion of cells expresses ion translocation-based
927 optogenetic tools such as ion-channels or ion-pumps, the simultaneous activation of these tools can
928 lead to transient but significant changes in the ion composition of the local extracellular space, thereby
929 indirectly affecting nearby non-opsin expressing neurons [249]. Electrophysiological characterization of
930 the optogenetic manipulation can be performed to quantify the extent of such unintended effects,
931 allowing the optimization of light power and illumination paradigms. Optogenetic tools that modulate
932 biochemical activity within the cells or ones that act on slower timescales, or only induce subthreshold

depolarization, are less prone to the caveats imposed by highly synchronous neuronal activation [250]. Finally, optogenetic firing rate modulation experiments are mostly designed to acutely alter the firing rates of targeted cells, which can have different effects than chronic manipulations. Brain circuits regulate their overall activity to achieve a homeostatic equilibrium, such that when the firing rate of a circuit is transiently increased or decreased, it can acutely affect the independent functions of downstream circuits and lead to markedly different results compared with chronic manipulations[250]. Acute effects are normally more severe, and could lead to overestimation of the roles of targeted regions in a given behavior. While chronic manipulations such as lesions do not suffer from this limitation, plastic changes during lesion recovery can also lead to an underestimation of the necessity of a given input to a local circuit. In summary, a sound experimental strategy should balance the use of acute and powerful optogenetic approaches with chronic experiments, pharmacological manipulations or lesions, and use caution in claims of causality based purely on manipulations that might suffer from any of the above-mentioned artifacts.

[H1] Outlook

[H2] Refinement of the optogenetic toolbox

We anticipate a further optimization of existing tools in terms of kinetics, ion or substrate selectivity, and widening of the spectral range from UV to the near-infrared to enhance the use of optogenetics. Additional light-activated enzymes allowing for optogenetic control beyond cell excitability are still to be discovered. Efforts are currently directed at optogenetic control of translation, transcription, nucleotide modification and epigenetics, as well as protein degradation. We are also expecting better tools for the control of cellular mechanics, development and differentiation.

[H2] Enhancement of basic research

Optogenetics will further advance the investigation of neural circuits. This will not only establish links of causality between neural activity and behavior but eventually generate sufficient knowledge for a theory of the brain to emerge. Empirically observed neural activity in optogenetic experiments taking into account the activity of individual neurons may eventually allow deriving the neural code, which, when integrated into a solid theoretical framework, will bring the neurosciences at par with other fields of natural sciences.

Optogenetics may also drive basic knowledge in other fields of life science, from cardiac physiology to plant physiology. For plant optogenetics, which is still in its infancy, there is great potential through the recently introduced in planta retinal synthesis, which now allows access for many rhodopsin-based manipulations. Implementing optogenetic approaches in any system of excitable cells will allow for the investigation of so far intangible questions. This may apply for example to the control of muscle contraction in the heart as well as the insulin secretion in the pancreas.

[H2] Open routes of translation

Beyond advancing basic science, optogenetics also has translational potential, either by inspiring novel protocols of existing therapies or as a therapy in humans. Several possible optogenetically-inspired medical interventions and therapies are already outlined in this review. Optogenetics can be used in vitro to analyze cellular processes in single cells, cultured tissue or brain slices. Optogenetics can also simulate clinically-relevant scenarios in animal models of brain diseases, including optogenetics-informed electrical stimulation protocols or closed-feedback control schemes. Possible indications are epilepsy, Parkinson's disease or addiction. Some of these interventions may eventually be emulated in humans, for example with refined deep brain stimulation protocols or pharmacology (Supplementary Figure 12).

With the recent proof-of-principle of optogenetic vision restoration in humans with RP, longer-term gene therapy options remain open for optogenetics, though several challenges need to be addressed. Optimization of gene delivery vectors that are safe and produce long-lasting expression and optimization of light delivery to the desired organ is essential. Light delivery deep into the tissue, beyond the limited optical depth penetration minimizing the use of optical fibers is also needed. One non-conventional solution is to introduce in situ sources of biological light, such as luminopsins. Triggered by a chemical process like simple substrate delivery, these luminopsins do not require device implantation and can be tuned to control inhibitory or excitatory actuators. Further remote trigger methods involve energy-conversion schemes via mechanoluminescent nanoparticles. The energy could be provided by intermittent focused ultrasound, thus recharging light emitting materials that can deliver short opsin-engaging pulses. Mechanosensitive TRAAK K+ channel for example could be specifically activated by ultrasound with submillisecond kinetics [251] providing a new, orthogonal dimension for external non-invasive manipulation of neural circuits.

Clinical applications of optogenetics to the heart face many challenges compared to the more accessible, immune-privileged applications to the eye that have seen translational advances. Considering the potential impact for control of arrhythmias, efforts should continue to improve the genetic targeting by more specific promoters, safer viral vectors, longer-wavelength opsins for better tissue penetration and miniaturized distributed light sources. Basic science experiments with optogenetic tools provide invaluable insights for improvement of current cardiac devices and may yield new strategies for arrhythmia control [112,193]. In the meantime, optogenetics-empowered high-throughput systems can more immediately improve cardiotoxicity testing and drug development. Similarly, in vitro assays for drug development and personalized medicine may use humanized optogenetic tools, patient-derived cells and engineered tissues coupled with highly parallel all-optical electrophysiology techniques to yield a low-cost, faster and more efficient drug-development pipeline.

Likewise, scalable optogenetic control of living plants, as discussed here, or microbes can be leveraged to address problems related to energy, food, biotechnology and climate challenges. As these do not involve deployment in the human body, they can be implemented on a shorter time scale, with less technical and regulatory obstacles.

Acknowledgements:

This work was supported by the following funding sources: V.E. is supported by the IHU FOReSIGHT grant (Grant P-ALLOP3-IHU-000), the Axa research funding the European Research Council (ERC-2019-AdG; No. 885090) and the Agence National pour la Recherche (ANR-17-CE16-0021). E.E is supported in part by grants NIH R01 HL144157, NIH R21EB026152, NSF 1705645, NSF 1830941. R.H is supported by the German Research Foundation (DFG), Koselleck award, HE1640/42-1. P.H. is supported by the German Research Foundation (DFG) (SFB1078, SPP1926, UniSysCat and Neurocure) and the ERC (Stardust 767092) P.H. is Hertie Professor for Neuroscience and supported by the Hertie Foundation. C.L. is supported by the ERC (ERC-2020-AdG, F-addict) and the Swiss National Science Foundations (No 310030_189188 and CRSII5_186266). M.M has received funding from the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No. 844492. Z.H.P is supported by the Ligon Research Center of Vision at Kresge Eye Institute, Dryer Foundation, Herrick Foundation, and Research to Prevent Blindness to Department of Ophthalmology, Visual and Anatomical Sciences at Wayne State

University School of Medicine. O.Y is supported by the Joseph and Wolf Lebovic Charitable Foundation Chair for Research in Neuroscience, the European Research Council (grant #819496), the EU Horizon2020 program (H2020-ICT-2018-20 DEEPER 101016787) and by the Israel Science Foundation (grant #3131/20).

Author contributions

Introduction (P.H., V.E., E.E., R.R.H., C.L., M.M., Z.-H.P., J.V. and O.Y.); Experimentation (P.H., V.E., M.M., J.V. and O.Y.); Results (P.H., V.E., E.E., R.R.H., K.R.K., C.L., M.M., Z.-H.P., R.S., J.V. and O.Y.); Applications (P.H., V.E., E.E., R.R.H., K.R.K., C.L., M.M., Z.-H.P., R.S. and O.Y.); Reproducibility and data deposition (P.H., V.E., E.E., R.R.H., K.R.K., C.L., M.M., Z.-H.P., R.S., J.V. and O.Y.); Limitations and optimizations (P.H., V.E., E.E., R.R.H., C.L., Z.-H.P., J.V. and O.Y.); Outlook (P.H., V.E., E.E., R.R.H., C.L., Z.-H.P. and O.Y.); Overview of the Primer (P.H. and O.Y.). Authors are listed in alphabetical order.

Competing interests

Z.-H.P. is a co-inventor on patents related to optogenetic vision restoration and is also a co-founder and scientific advisor of Ray Therapeutics. The other authors declare no competing interests.

Peer review information

Nature Reviews Methods Primers thanks John Flannery and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

Supplementary information

Supplementary information is available for this paper at https://doi.org/10.1038/s415XX-XXX-XXXX-X

Glossary terms:

Microelectrode: an electrode with micrometer-sized tip used to record single neuron activity.

Optrode: an electrode coupled to an optical fiber used to record and manipulate neural activity in cells expressing an optogenetic actuator.

Optogenetic actuator: a light sensitive protein that transiently modifies cellular properties during illumination.

Bidirectional voltage modulation: Changing the voltage in the depolarizing (excitatory) or hyperpolarizing (inhibitory) directions.

Immediate early genes: genes that are rapidly induced by elevated neural activity such as *c-Fos*.

Optical clamp: Using light and real-time feedback to keep membrane electrical parameters, such as voltage or action potential shape, at set desired value.

Antidromic activation: Retrograde propagation of an action potential from the axon to the neuronal soma.

Figure legends

Figure 1. Principles of Optogenetics. DNA encoding a sensory photoreceptor derived from a microorganism, plant or animal (orange) is cloned under the regulation of control elements that allow the targeting of specific host cells (blue), packed into a vector such as a viral vector or bacteria and injected into the tissue, organ or organism of interest. The targeted cell (orange) now expresses the light-sensitive protein and can be controlled with light in a variety of ways, depending on the specific photoreceptor expressed.

Figure 2. The optogenetic actuator toolbox. a) Key advances in the development of optogenetic tools. Not all available tools are highlighted here. Major developments are shown above the arrow, and first applications of channelrhodopsins to model organisms including humans are shown below the arrow. **B)** Tools for optogenetic manipulation of membrane voltage and local ion concentrations (top), second-messenger, G-protein-signaling and kinase-signaling (middle) and the light-controlled interaction of photoreceptors with tethered partner proteins for subcellular application (bottom). LOV-domain based dimerizers expose a "aged"signaling peptide after light-triggered unfolding of the Jα-Helix[252]. Cryptochrome 2 and Phytochrome B interact with CiBN or PIF-domains after blue or red light absorption respectively[253,254] **c)** Commonly-used optogenetic tools for excitation or inhibition of neuronal activity including cation conducting ChRs e*Ts*ChR[255], Cheriff[205], *Co*ChR[30], *Cr*ChR2$_{TC}$[256], ChroME[104] and derivatives, SSFO/Soul[120,257], ChRmine[258], bReaChES[259] and f-Chrimson[117], chloride and potassium conducting ChRs (e.g. GtACR1, GtACR2[219] and *Hc*KCR1[22]), inward directed proton pumps (e.g. *Ns*XeR[260]) and outward directed proton, sodium and chloride pumps (e.g. Arch3.0[171], eKR2[261], eNpHR3.0[262]), all plotted according to their peak excitation wavelength and temporal kinetics. **D)** The soluble enzyme bPAC[62] and the rhodopsin-guanyl-cyclase *Ca*RhGC[68] produce cAMP and cGMP following illumination whereas the non-bleaching opsins mOPN4[48], eOPN3[54], PPO[53] and JellyOP[47] activate different G-protein pathways. **e:** Genetically encoded sensors with diverse excitation spectra (depicted on the x axis) can be used to monitor changes in Ca2+ voltage, and pH, such as GCaMP and R-CaMP[156]and FRCaMP[263] for Ca^{2+}, ASAP3[264], Voltron[265], VARNAM[266], Quasar[205] and Archon[267] for voltage,

and pHluorin[268] for pH. In experiments combining sensors and actuators, both need to be chosen carefully to minimize optical crosstalk.

Figure 3. Cell-type specific targeting of optogenetic tools. **A**) Transgenic mice constitutively expressing an opsin gene from their genome allow simple experiments that only require the addition of a light-delivery apparatus. Promoter "A" activity (indicated by A) will lead to transgene expression (indicated in green). **B)** A transgenic animal expressing a recombinase such as Cre under the control of a cell-type specific promoter is crossed with a second line carrying a conditional expression cassette encoding the desired opsin. Dual transgenic offspring will then show organism-wide expression of the opsin in all cells that underwent promoter activation at any stage of development (indicated in green). Cre expression (indicated by A) is unnecessary once the conditional expression cassette was activated. **C)** Where a short minimal promoter sequence is available, targeted viral vector injections can be used to restrict expression spatially as well as by the gene expression profile. A viral vector containing the specific minimal promoter sequence upstream of the opsin gene will lead to expression in specific cells expressing the promoter (indicated by A), only in the region targeted with the injection (indicated by the blue box). **D)** Approaches a and b can be combined to achieve both spatial and gene expression specificity in cases where short specific promoters are not available, or where promoter activity is not specific during development. **e:** Projection neurons can be addressed by injection of an axon terminal-transducing, retrograde traveling viral vector encoding for the opsin or a recombinase into the target region. The recombinase encoding viral vector is injected in a projection target (area B, indicated by the red box) and travels retrogradely. A second viral injection of conditional expression cassette encoding the desired opsin into an upstream region (area A, indicated by the blue box) will then lead to opsin expression only in neurons within area A that project to area B **f**: AAV capsids engineered for improved blood-brain barrier penetration allow brain-wide (mostly sparse) expression of an opsin through intravenous injection of the viral vector.

Figure 4. Optical approaches for optogenetic stimulation. a-c) Single-photon wide-field illumination (indicated in blue) of all genetically targeted opsin-expressing neurons using excitation through optical fibers. **a)** Illumination using a flat cleaved optical fiber causes high peak light power density at the fiber-tissue interface. **b)** A tapered fiber increases the optical fiber-tissue interface resulting in a reduced peak light power density. **c)** Single-photon multi-target patterned illumination by spatially shaping the intensity of the excitation beam by means of a digital micromirror device (DMD), placed in a plane conjugated to the sample plane. The light distribution at the DMD plane and at the sample plane only differ by a spatial scaling factor corresponding to the magnification of the optical system. The axial resolution is proportional to the square of the lateral spot dimensions. **d-e**) Two-photon multi-target illumination by holographic light shaping: **d)** a spatial light modulator (SLM) placed at a plane conjugated with the objective back aperture, generates a 3D distribution of holographic spots which are scanned with a spiral trajectory to cover the cell surface. The axial extension of the generated spot is optimized to illuminate the upper and lower cell membranes. **e)** An SLM is used to generate multiple extended spots with a size large enough to cover the whole cell soma. Temporal focusing is

used to maintain micrometer axial resolution independently of the lateral spot size. . **f)** A timeline indicating critical optical developments which have enabled new optogenetic experiments throughout the past fifteen years. Single- photon and two-photon milestones are colored in blue and red respectively. Holographic light shaping for neuronal activation was developed simultaneously for single- and two- photon activation as indicated by the red-blue gradient for the milestone in **f)**.

Figure 5: Expected results in optogenetic experiments. A) Expression of optogenetic actuators such as ChR2 or NpHR in neurons leads to the emergence of light-driven photocurrents, which can be recorded using the whole-cell patch clamp technique (left). Cells expressing the chloride-conducting NpHR will show an outward current (top right, voltage clamp recording with cell resting at -70 mV) while cells expressing the cation-conducting ChR2 will show an inward photocurrent (bottom right, voltage clamp recording with cell resting at -70 mV). **B)** Whole-cell current-clamp recordings in a neuron expressing the excitatory ChR2, showing action potentials evoked by brief light pulses (blue bars). **C)** Hyperpolarization and silencing of spontaneously-occurring action potentials in a neuron expressing eNpHR3.0. **d)** Extracellular recordings, coupled with local light delivery, used to reveal the activity of neurons in vivo, using the awake behaving optrode configuration[269] **e)** Raster plot showing action potentials (represented as black dots) occurring rapidly after a 5-ms blue light pulse delivered into the target brain region. **F)** Raster plot showing the activity of neurons expressing the inhibitory anion-conducting GtACR2, showing increased inhibition of action potential firing with increasing light intensity. Part F is reprinted from ref X, CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/).

Figure 6. Establishing links of causality with optogenetics. Experimental road map based on identifying the neural correlate of behavioral sensitization to cocaine[270]. A) When injected, cocaine elicits a locomotor response quantified in a cyclotron. The response is enhanced upon a second injection of the same dose. B) *c-Fos* is an immediate early gene highlighting the neurons particularly active, which provided the entry point to identifying the mPFC to NAc projection as the behavioral relevant circuit. C) Slice electrophysiology enables observation of the selective potentiation of glutamate transmission onto D1R-MSNs[271]. D) A depotentiation protocol (LTD at 12Hz) validated in slices restores standard transmission. E) In vivo validation involves opto-tagging, where spontaneously occurring spikes (grey, dashed trace) are compared to optogenetically-evoked spikes (blue trace). Waveform and latency are important parameters. F) The LTD protocol is eventually applied in vivo to reverse sensitization. Part B adapted with permission from ref X, PUBLISHER. Part D adapted with permission from ref X, PUBLISHER.

Figure 7. Optogenetic application for vision restoration, cardiac research, plant modification. A) Strategies for optogenetic restoration of vision following photoreceptor degeneration. (Aa) Visual processing pathways in the normal retina, illustrating the rod/cone, ON/OFF pathways and the antagonistic center–surround receptive fields of retinal ganglion cells. ON cells, including rod bipolar cells and AII amacrine cells, are shown in gray tones, and OFF cells are shown in black. The ON and OFF regions of the receptive field of retinal ganglion cells are indicated by + and −, respectively. (Ab) Ubiquitous expression of a depolarizing optogenetic tool (green) in all retinal ganglion cells to convert them to ON cells. (Ac) Targeting a depolarizing optogenetic tool in ON bipolar cells to produce ON and OFF response in retinal ganglion cells and possibly the center–surround receptive fields. Abbreviations: AII, AII amacrine cells; BC,

bipolar cells; RBC, rod bipolar cells. (Modified from [272]). **B)** Optogenetics in cardiac research. Ba) Cell-specific targeting is used for the sympathetic (red) and parasympathetic (blue) nervous control of the heart using TH and CHAT promoters; cardiomyocytes (CM) from the upper or lower chambers of the heart (atria, A, or ventricles, V) can be selectively light-sensitized; specific targeting of the fast conduction system (CS), cardiac fibroblasts (FB), vascular cells (VC) or macrophages (M) is also of interest. (Bb). Rhythm control can include optical pacemaking by short pulses (top trace), heart rate modulation by low-level constant (middle trace) or pulsed light by activating the sympathetic nervous system (increase) or the parasympathetic nervous system (decrease), and arrhythmias can be terminated to restore normal rhythm through a single long pulse (bottom trace), series of pulses and/or spatially-patterned light. Bc) Cardiotoxicity testing, a required component in drug development, is enabled by high-throughput optogenetic platforms, which can integrate patient-derived iPSC-cardiomyocytes for personalized therapy.. **C)** Optogenetic approaches in plants. Ca) This scheme displays carbon dioxide entering through the stomata with loss of water and oxygen. Cb-Cg: Expression of rhodopsins to control plant cell behavior. Cb) Absorbance spectra of anion channelrhodopsins GtACR1 (black) in relation to endogenous relevant plant photoreceptors. Cc) Optical fiber illumination of a leaf from an Arabidopsis plant mounted in a microscope setup for Cd) simultaneous optical stimulation and electric recordings of guard cells embedded in the leaf epidermis. Ce) A representative membrane voltage recording from wild-type tobacco (red) and tobacco with stable GtACR1 expressing guard cell (black) in response to a 525 nm light pulse (10s) of 0.57 mW/mm^2 in the presence of background red-light (630 nm, 0.018 mW/mm^2) to elicit stomatal opening. Cf and Cg). Closure of the stomatal aperture is only induced in GtACR1-expressing cells in the presence of green light, indicated by the green bar in Cf and the green light spot in Cg. Part A adapted with permission from ref X, PUBLISHER. Part Cc, image courtesy of COPYRIGHT HOLDER. Parts Cd, Cf and Cg adapted with permission from ref X, PUBLISHER.

Box 1: Compartment-specific functions of microbial rhodopsins.

ACRs (such as GtACR2, iC++ and iChloc) can be used to control the chloride conductance in a light dependent manner. However, the effect on neuronal excitability depends on the chloride reversal potential, which can differ between subcellular compartments, as well as the membrane potential. The left schematic shows a neuron colored according to the typical chloride reversal potential. In the somatic compartment (top inset) **s**hunting inhibition occurs, if the reversal potential of a channel is close to the resting membrane potential of the cell. In this case, its activation does not lead to a substantial current, but rather to a conductance that will oppose any change of the membrane potential from the channel reversal potential, referred to as shunting conductance. The input resistance of the neuron is reduced, causing a smaller amplitude of subsequent excitatory potentials. If the channel reversal potential lies between the resting potential and the action potential threshold, however, the effects of shunting inhibition are more complex. In this case, ACR activation will lead to a depolarization, but excitatory potential amplitudes will still

be reduced. Consequently, ACR activation will still lead to a reduced spike rate. Upon channel closing the input resistance then increases while the membrane potential is still depolarized, leading to a transiently increased excitability. Furthermore, if ACRs are activated over extended periods of excitatory drive, Cl^- can accumulate in the cell, and the depolarizing phase of shunting inhibition will become more accentuated, leading to activity-dependent effects of shunting inhibition. At the presynaptic terminal (bottom) ACR activation leads to depolarization, and potentially even action potential initiation, especially at light onset when the pool of activatable voltage gated sodium channels is large. ACR based optogenetic manipulations should thus take the unique features of compartment-specific physiology into account.

Box 2: Single-photon vs two-photon excitation, mechanism and focal volume

In single-photon (1P) excitation the absorption of a photon by a chromophore induces a molecular transition from the ground state (S0) to the excited electronic state (S1), while in two-photon (2P) excitation, the same transition can be induced by the quasi-simultaneous absorption of two photons. Since 2P cross-sections are typically much smaller than those for 1P, significantly higher photon fluxes are generally required to generate similar excitation rates, requiring more complex and expensive components such as ultrafast lasers. There are two main implications of two photon absorption in microscopy. First, since the probability of excitation is a quadratic function of the instantaneous photon density, targets at the focal plane are much more likely excited than out of focus targets, whereas in 1P excitation all targets throughout the light path can be excited. Second, the use of photons of lower energy and therefore of longer wavelengths (deep red and IR) can penetrate more deeply (~700 μm) in scattering tissue.

References

1 Famintzin, A. *Die Wirkung der Lichtes auf die Bewegung der Chlamidomonas pulvisculus Ehr., Euglena viridis Ehr. und Orcillatoria insignis Tw*. (1866).

2 Kuhne, W. F. *Zur Photochemie der Netzhaut*. (Carl Winter's Universitatsbuchhandlung, 1877).

3 Darwin, C. *The Power of Movements in Plants*. (Appleton, 1881).

4 Zemelman, B. V., Lee, G. A., Ng, M. & Miesenböck, G. Selective photostimulation of genetically chARGed neurons. *Neuron* **33**, 15-22 (2002).

5 Boyden, E. S., Zhang, F., Bamberg, E., Nagel, G. & Deisseroth, K. Millisecond-timescale, genetically targeted optical control of neural activity. *Nature Neuroscience* **8**, 1263-1268 (2005).

6 Ishizuka, T., Kakuda, M., Araki, R. & Yawo, H. Kinetic evaluation of photosensitivity in genetically engineered neurons expressing green algae light-gated channels. *Neuroscience Research* **54**, 85-94 (2006).

7 Li, X. *et al.* Fast noninvasive activation and inhibition of neural and network activity by vertebrate rhodopin and green algae channelrhodopsin. *Proceedings of the National Academy of Sciences of the United States of America* **102**, 17816-17821 (2005).
8 Nagel, G. *et al.* Light activation of channelrhodopsin-2 in excitable cells of Caenorhabditis elegans triggers rapid Behavioral responses. *Current Biology* **15**, 2279-2284 (2005).
9 Schroll, C. *et al.* Light-induced activation of distinct modulatory neurons triggers appetitive or aversive learning in Drosophila larvae. *Current Biology* **16**, 1741-1747 (2006).
10 Adamantidis, A. R., Zhang, F., Aravanis, A. M., Deisseroth, K. & De Lecea, L. Neural substrates of awakening probed with optogenetic control of hypocretin neurons. *Nature* **450**, 420-424 (2007).
11 Douglass, A. D., Kraves, S., Deisseroth, K., Schier, A. F. & Engert, F. Escape behavior elicited by single, channelrhodopsin-2-evoked spikes in zebrafish somatosensory neurons. *Current biology* **18**, 1133-1137 (2008).
12 Han, X. *et al.* Millisecond-timescale optical control of neural dynamics in the nonhuman primate brain. *Neuron* **62**, 191-198 (2009).
13 Bi, A. D. *et al.* Ectopic expression of a microbial-type rhodopsin restores visual responses in mice with photoreceptor degeneration. *Neuron* **50**, 23-33 (2006).
14 Ronzitti, E. *et al.* Recent advances in patterned photostimulation for optogenetics. *Journal of Optics* **19**, 113001 (2017).
15 Hull, K., Morstein, J. & Trauner, D. In vivo photopharmacology. *Chemical reviews* **118**, 10710-10747 (2018).
16 Velema, W. A., Szymanski, W. & Feringa, B. L. Photopharmacology: beyond proof of principle. *Journal of the American Chemical Society* **136**, 2178-2191 (2014).
17 Kolar, K., Knobloch, C., Stork, H., Žnidarič, M. & Weber, W. OptoBase: a web platform for molecular optogenetics. *ACS synthetic biology* **7**, 1825-1828 (2018).
18 Manoilov, K. Y., Verkhusha, V. V. & Shcherbakova, D. M. A guide to the optogenetic regulation of endogenous molecules. *Nature methods* **18**, 1027-1037 (2021).
19 Nagel, G. *et al.* Channelrhodopsin-2, a directly light-gated cation-selective membrane channel. *Proceedings of the National Academy of Sciences of the United States of America* **100**, 13940-13945 (2003).
20 Rozenberg, A. *et al.* Lateral Gene Transfer of Anion-Conducting Channelrhodopsins between Green Algae and Giant Viruses. *Curr Biol* **30**, 4910-4920 e4915, doi:10.1016/j.cub.2020.09.056 (2020).
21 Vierock, J., Grimm, C., Nitzan, N. & Hegemann, P. Molecular determinants of proton selectivity and gating in the red-light activated channelrhodopsin Chrimson. *Sci Rep* **7**, 9928, doi:10.1038/s41598-017-09600-8 (2017).
22 Govorunova, E. G. *et al.* Kalium rhodopsins: Natural light-gated potassium channels. *bioRxiv* (2021).
23 Govorunova, E. G. *et al.* The Expanding Family of Natural Anion Channelrhodopsins Reveals Large Variations in Kinetics, Conductance, and Spectral Sensitivity. *Sci Rep* **7**, 43358, doi:10.1038/srep43358 (2017).
24 Mahn, M. *et al.* High-efficiency optogenetic silencing with soma-targeted anion-conducting channelrhodopsins. *Nature communications* **9**, 1-15 (2018).
25 Ben-Ari, Y. Excitatory actions of gaba during development: the nature of the nurture. *Nature Reviews Neuroscience* **3**, 728-739 (2002).
26 Schneider, F., Grimm, C. & Hegemann, P. Biophysics of channelrhodopsin. *Annual review of biophysics* **44**, 167-186 (2015).
27 Kuhne, J. *et al.* Unifying photocycle model for light adaptation and temporal evolution of cation conductance in channelrhodopsin-2. *Proc Natl Acad Sci U S A* **116**, 9380-9389, doi:10.1073/pnas.1818707116 (2019).
28 Sineshchekov, O. A., Govorunova, E. G., Li, H. & Spudich, J. L. Bacteriorhodopsin-like channelrhodopsins: Alternative mechanism for control of cation conductance. *Proc Natl Acad Sci U S A* **114**, E9512-E9519, doi:10.1073/pnas.1710702114 (2017).
29 Kishi, K. E. *et al.* Structural basis for channel conduction in the pump-like channelrhodopsin ChRmine. *Cell* **185**, 672-689. e623 (2022).
30 Klapoetke, N. C. *et al.* Independent optical excitation of distinct neural populations. *Nat Methods* **11**, 338-346, doi:10.1038/nmeth.2836 (2014).
31 Oda, K. *et al.* Crystal structure of the red light-activated channelrhodopsin Chrimson. *Nat Commun* **9**, 3949, doi:10.1038/s41467-018-06421-9 (2018).
32 Govorunova, E. G. *et al.* RubyACRs, non-algal anion channelrhodopsins with highly red-shifted absorption. *bioRxiv* (2020).
33 Gradinaru, V. *et al.* Molecular and Cellular Approaches for Diversifying and Extending Optogenetics. *Cell* **141**, 154-165, doi:Doi 10.1016/J.Cell.2010.02.037 (2010).
34 Vierock, J. *et al.* BiPOLES is an optogenetic tool developed for bidirectional dual-color control of neurons. *Nature Communications* **12**, 1-20 (2021).

36 Zhang, F. *et al.* Multimodal fast optical interrogation of neural circuitry. *Nature* **446**, 633-U634 (2007).
37 Parker, D. Neuronal network analyses: premises, promises and uncertainties. *Philosophical Transactions of the Royal Society B: Biological Sciences* **365**, 2315-2328 (2010).
38 Chuong, A. S. *et al.* Noninvasive optical inhibition with a red-shifted microbial rhodopsin. *Nature neuroscience* **17**, 1123-1129 (2014).
39 Wiegert, J. S., Mahn, M., Prigge, M., Printz, Y. & Yizhar, O. Silencing neurons: tools, applications, and experimental constraints. *Neuron* **95**, 504-529 (2017).
40 Rost, B. R. *et al.* Optogenetic acidification of synaptic vesicles and lysosomes. *Nature neuroscience* **18**, 1845-1852 (2015).
41 Junge, W. Protons, the thylakoid membrane, and the chloroplast ATP synthase. *Annals of the New York Academy of Sciences* **574**, 268-286 (1989).
42 Raimondo, J. V., Kay, L., Ellender, T. J. & Akerman, C. J. Optogenetic silencing strategies differ in their effects on inhibitory synaptic transmission. *Nature neuroscience* **15**, 1102-1104 (2012).
43 Khorana, H. G., Knox, B. E., Nasi, E., Swanson, R. & Thompson, D. a. Expression of a Bovine Rhodopsin Gene in Xenopus Oocytes - Demonstration of Light-Dependent Ionic Currents. *Proceedings of the National Academy of Sciences of the United States of America* **85**, 7917-7921 (1988).
44 Karunarathne, W. A., Giri, L., Patel, A. K., Venkatesh, K. V. & Gautam, N. Optical control demonstrates switch-like PIP3 dynamics underlying the initiation of immune cell migration. *Proceedings of the National Academy of Sciences* **110**, E1575-E1583 (2013).
45 Karunarathne, W. A., Giri, L., Kalyanaraman, V. & Gautam, N. Optically triggering spatiotemporally confined GPCR activity in a cell and programming neurite initiation and extension. *Proceedings of the National Academy of Sciences* **110**, E1565-E1574 (2013).
46 Masseck, O. A. *et al.* Vertebrate cone opsins enable sustained and highly sensitive rapid control of Gi/o signaling in anxiety circuitry. *Neuron* **81**, 1263-1273 (2014).
47 Bailes, H. J., Zhuang, L.-Y. & Lucas, R. J. Reproducible and sustained regulation of Gαs signalling using a metazoan opsin as an optogenetic tool. *PloS one* **7**, e30774 (2012).
48 Spoida, K. *et al.* Melanopsin variants as intrinsic optogenetic on and off switches for transient versus sustained activation of G protein pathways. *Current Biology* **26**, 1206-1212 (2016).
49 Lin, B., Koizumi, A., Tanaka, N., Panda, S. & Masland, R. H. Restoration of visual function in retinal degeneration mice by ectopic expression of melanopsin. *Proceedings of the National Academy of Sciences* **105**, 16009-16014 (2008).
50 Tsunematsu, T., Tanaka, K. F., Yamanaka, A. & Koizumi, A. Ectopic expression of melanopsin in orexin/hypocretin neurons enables control of wakefulness of mice in vivo by blue light. *Neuroscience research* **75**, 23-28 (2013).
51 Koyanagi, M. *et al.* in *Optogenetics* 141-151 (Springer, 2021).
52 Eickelbeck, D. *et al.* Lamprey Parapinopsin ("UVLamP"): a bistable UV-sensitive optogenetic switch for ultrafast control of GPCR pathways. *ChemBioChem* **21**, 612 (2020).
53 Copits, B. A. *et al.* A photoswitchable GPCR-based opsin for presynaptic inhibition. *Neuron* **109**, 1791-1809. e1711 (2021).
54 Mahn, M. *et al.* Efficient optogenetic silencing of neurotransmitter release with a mosquito rhodopsin. *Neuron* **109**, 1621-1635. e1628 (2021).
55 Kim, J.-M. *et al.* Light-driven activation of β2-adrenergic receptor signaling by a chimeric rhodopsin containing the β2-adrenergic receptor cytoplasmic loops. *Biochemistry* **44**, 2284-2292 (2005).
56 Airan, R. D., Thompson, K. R., Fenno, L. E., Bernstein, H. & Deisseroth, K. Temporally precise in vivo control of intracellular signalling. *Nature* **458**, 1025-1029 (2009).
57 Osorno, T. *et al.* Light control of G protein signaling pathways by a novel photopigment. *Plos one* **13**, e0205015 (2018).
58 Bradley, S. J. & Challiss, R. J. G protein-coupled receptor signalling in astrocytes in health and disease: a focus on metabotropic glutamate receptors. *Biochemical pharmacology* **84**, 249-259 (2012).
59 Grusch, M. *et al.* Spatio-temporally precise activation of engineered receptor tyrosine kinases by light. *The EMBO journal* **33**, 1713-1726 (2014).
60 Kainrath, S., Stadler, M., Reichhart, E., Distel, M. & Janovjak, H. Green-Light-Induced Inactivation of Receptor Signaling Using Cobalamin-Binding Domains. *Angewandte Chemie International Edition* **56**, 4608-4611 (2017).

61 Chang, K.-Y. *et al.* Light-inducible receptor tyrosine kinases that regulate neurotrophin signalling. *Nature communications* **5**, 1-10 (2014).
62 Stierl, M. *et al.* Light modulation of cellular cAMP by a small bacterial photoactivated adenylyl cyclase, bPAC, of the soil bacterium Beggiatoa. *J Biol Chem* **286**, 1181-1188, doi:10.1074/jbc.M110.185496 (2011).
63 Bernal Sierra, Y. A. *et al.* Potassium channel-based optogenetic silencing. *Nat Commun* **9**, 4611, doi:10.1038/s41467-018-07038-8 (2018).
64 De Marco, R. J., Groneberg, A. H., Yeh, C. M., Castillo Ramirez, L. A. & Ryu, S. Optogenetic elevation of endogenous glucocorticoid level in larval zebrafish. *Front Neural Circuits* **7**, 82, doi:10.3389/fncir.2013.00082 (2013).
65 Jansen, V. *et al.* Controlling Fertilization and cAMP Signaling in Sperm Flagella by Optogenetics. *e-Life* **4**, UNSP e05161 (2015).
66 Zhang, S. X. *et al.* Hypothalamic dopamine neurons motivate mating through persistent cAMP signalling. *Nature*, 1-5 (2021).
67 Scheib, U. *et al.* The rhodopsin-guanylyl cyclase of the aquatic fungus Blastocladiella emersonii enables fast optical control of cGMP signaling. *Sci Signal* **8**, rs8, doi:10.1126/scisignal.aab0611 (2015).
68 Scheib, U. *et al.* Rhodopsin-cyclases for photocontrol of cGMP/cAMP and 2.3 A structure of the adenylyl cyclase domain. *Nat Commun* **9**, 2046, doi:10.1038/s41467-018-04428-w (2018).
69 Gao, S. *et al.* Optogenetic manipulation of cGMP in cells and animals by the tightly light-regulated guanylyl-cyclase opsin CyclOp. *Nature communications* **6**, 1-12 (2015).
70 Broser, M. *et al.* NeoR, a near-infrared absorbing rhodopsin. *Nature communications* **11**, 1-10 (2020).
71 Rost, B. R., Schneider-Warme, F., Schmitz, D. & Hegemann, P. Optogenetic tools for subcellular applications in neuroscience. *Neuron* **96**, 572-603 (2017).
72 Polesskaya, O. *et al.* Optogenetic regulation of transcription. *BMC neuroscience* **19**, 3-13 (2018).
73 Polstein, L. R. & Gersbach, C. A. Light-inducible spatiotemporal control of gene activation by customizable zinc finger transcription factors. *Journal of the American Chemical Society* **134**, 16480-16483 (2012).
74 Konermann, S. *et al.* Optical control of mammalian endogenous transcription and epigenetic states. *Nature* **500**, 472-+, doi:Doi 10.1038/Nature12466 (2013).
75 Nihongaki, Y., Kawano, F., Nakajima, T. & Sato, M. Photoactivatable CRISPR-Cas9 for optogenetic genome editing. *Nature biotechnology* **33**, 755-760 (2015).
76 Nihongaki, Y. *et al.* CRISPR–Cas9-based photoactivatable transcription systems to induce neuronal differentiation. *Nature methods* **14**, 963-966 (2017).
77 Raper, A. T., Stephenson, A. A. & Suo, Z. Functional insights revealed by the kinetic mechanism of CRISPR/Cas9. *Journal of the American Chemical Society* **140**, 2971-2984 (2018).
78 Arenkiel, B. R. *et al.* In vivo light-induced activation of neural circuitry in transgenic mice expressing channelrhodopsin-2. *Neuron* **54**, 205-218 (2007).
79 Madisen, L. *et al.* A toolbox of Cre-dependent optogenetic transgenic mice for light-induced activation and silencing. *Nature neuroscience* **15**, 793-802 (2012).
80 Madisen, L. *et al.* Transgenic mice for intersectional targeting of neural sensors and effectors with high specificity and performance. *Neuron* **85**, 942-958 (2015).
81 Lammel, S. *et al.* Diversity of transgenic mouse models for selective targeting of midbrain dopamine neurons. *Neuron* **85**, 429-438 (2015).
82 Song, A. J. & Palmiter, R. D. Detecting and avoiding problems when using the Cre–lox system. *Trends in Genetics* **34**, 333-340 (2018).
83 Graybuck, L. T. *et al.* Prospective, brain-wide labeling of neuronal subclasses with enhancer-driven AAVs. *BioRxiv*, 525014 (2019).
84 Nair, R. R., Blankvoort, S., Lagartos, M. J. & Kentros, C. Enhancer-driven gene expression (EDGE) enables the generation of viral vectors specific to neuronal subtypes. *Iscience* **23**, 100888 (2020).
85 Jüttner, J. *et al.* Targeting neuronal and glial cell types with synthetic promoter AAVs in mice, non-human primates and humans. *Nature Neuroscience* **22**, 1345-1356 (2019).
86 Tervo, D. G. R. *et al.* A designer AAV variant permits efficient retrograde access to projection neurons. *Neuron* **92**, 372-382 (2016).
87 Zhang, S. *et al.* Long-range and local circuits for top-down modulation of visual cortex processing. *Science* **345**, 660-665 (2014).
88 Chan, K. Y. *et al.* Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems. *Nature neuroscience* **20**, 1172-1179 (2017).

89 Challis, R. C. *et al.* Systemic AAV vectors for widespread and targeted gene delivery in rodents. *Nature protocols* **14**, 379-414 (2019).
90 Mathiesen, S. N., Lock, J. L., Schoderboeck, L., Abraham, W. C. & Hughes, S. M. CNS Transduction Benefits of AAV-PHP. eB over AAV9 Are Dependent on Administration Route and Mouse Strain. *Molecular Therapy-Methods & Clinical Development* **19**, 447-458 (2020).
91 LoTurco, J., Manent, J.-B. & Sidiqi, F. New and improved tools for in utero electroporation studies of developing cerebral cortex. *Cerebral cortex* **19**, i120-i125 (2009).
92 Dal Maschio, M. *et al.* High-performance and site-directed in utero electroporation by a triple-electrode probe. *Nature communications* **3**, 1-11 (2012).
93 Rosin, J. M. & Kurrasch, D. M. In utero electroporation induces cell death and alters embryonic microglia morphology and expression signatures in the developing hypothalamus. *Journal of neuroinflammation* **15**, 1-15 (2018).
94 Mahn, M., Prigge, M., Ron, S., Levy, R. & Yizhar, O. Biophysical constraints of optogenetic inhibition at presynaptic terminals. *Nature neuroscience* **19**, 554-556 (2016).
95 Ullrich, S., Gueta, R. & Nagel, G. Degradation of channelopsin-2 in the absence of retinal and degradation resistance in certain mutants. *Biological chemistry* **394**, 271-280 (2013).
96 Hofherr, A., Fakler, B. & Klöcker, N. Selective Golgi export of Kir2. 1 controls the stoichiometry of functional Kir2. x channel heteromers. *Journal of cell science* **118**, 1935-1943 (2005).
97 Mattis, J. *et al.* An analysis of new and existing opsins for scientific application. *European Biophysics Journal with Biophysics Letters* **40**, 68-69 (2011).
98 Zhou, Y. *et al.* Optogenetic control of plant growth by a microbial rhodopsin. *Nature Plants* **7**, 144-151 (2021).
99 Adam, Y. *et al.* Voltage imaging and optogenetics reveal behaviour-dependent changes in hippocampal dynamics. *Nature* **569**, 413-417 (2019).
100 Wu, C., Ivanova, E., Zhang, Y. & Pan, Z.-H. rAAV-mediated subcellular targeting of optogenetic tools in retinal ganglion cells in vivo. *PloS one* **8**, e66332 (2013).
101 Baker, C. A., Elyada, Y. M., Parra, A. & Bolton, M. M. Cellular resolution circuit mapping with temporal-focused excitation of soma-targeted channelrhodopsin. *Elife* **5**, e14193 (2016).
102 Shemesh, O. A. *et al.* Temporally precise single-cell-resolution optogenetics. *Nature neuroscience* **20**, 1796-1806 (2017).
103 Forli, A. *et al.* Two-photon bidirectional control and imaging of neuronal excitability with high spatial resolution in vivo. *Cell reports* **22**, 3087-3098 (2018).
104 Mardinly, A. R. *et al.* Precise multimodal optical control of neural ensemble activity. *Nature neuroscience* **21**, 881-893 (2018).
105 Forli, A., Pisoni, M., Printz, Y., Yizhar, O. & Fellin, T. Optogenetic strategies for high-efficiency all-optical interrogation using blue-light-sensitive opsins. *Elife* **10**, e63359 (2021).
106 Spaulding, E. L. & Burgess, R. W. Accumulating evidence for axonal translation in neuronal homeostasis. *Frontiers in neuroscience* **11**, 312 (2017).
107 Johnson, H. E. & Toettcher, J. E. Illuminating developmental biology with cellular optogenetics. *Current opinion in biotechnology* **52**, 42-48 (2018).
108 Stujenske, J. M., Spellman, T. & Gordon, J. A. Modeling the spatiotemporal dynamics of light and heat propagation for in vivo optogenetics. *Cell reports* **12**, 525-534 (2015).
109 Rungta, R. L., Osmanski, B.-F., Boido, D., Tanter, M. & Charpak, S. Light controls cerebral blood flow in naive animals. *Nature communications* **8**, 1-9 (2017).
110 Pisanello, M. *et al.* Tailoring light delivery for optogenetics by modal demultiplexing in tapered optical fibers. *Scientific reports* **8**, 1-11 (2018).
111 Arrenberg, A. B., Stainier, D. Y., Baier, H. & Huisken, J. Optogenetic control of cardiac function. *Science* **330**, 971-974 (2010).
112 Burton, R. A. *et al.* Optical control of excitation waves in cardiac tissue. *Nature photonics* **9**, 813-816 (2015).
113 Majumder, R. *et al.* Optogenetics enables real-time spatiotemporal control over spiral wave dynamics in an excitable cardiac system. *Elife* **7**, e41076 (2018).
114 Scardigli, M. *et al.* Real-time optical manipulation of cardiac conduction in intact hearts. *The Journal of physiology* **596**, 3841-3858 (2018).
115 Chen, I.-W., Papagiakoumou, E. & Emiliani, V. Towards circuit optogenetics. *Current opinion in neurobiology* **50**, 179-189 (2018).
116 Pégard, N. C. *et al.* Three-dimensional scanless holographic optogenetics with temporal focusing (3D-SHOT). *Nature communications* **8**, 1-14 (2017).

117 Mager, T. *et al.* High frequency neural spiking and auditory signaling by ultrafast red-shifted optogenetics. *Nature communications* **9**, 1-14 (2018).
118 Marshel, J. H. *et al.* Cortical layer–specific critical dynamics triggering perception. *Science* **365** (2019).
119 Lin, J., Knutsen, P., Muller, A., Kleinfeld, D. & Tsien, R. ReaChR: a red-shifted variant of channelrhodopsin enables neuronal activation through the intact skull. *Nat Neurosci* **16**, 1499-1508 (2013).
120 Yizhar, O. *et al.* Neocortical excitation/inhibition balance in information processing and social dysfunction. *Nature* **477**, 171-178 (2011).
121 Ronzitti, E. *et al.* Submillisecond optogenetic control of neuronal firing with two-photon holographic photoactivation of chronos. *Journal of Neuroscience* **37**, 10679-10689 (2017).
122 Chen, I.-W. *et al.* In vivo submillisecond two-photon optogenetics with temporally focused patterned light. *Journal of Neuroscience* **39**, 3484-3497 (2019).
123 Feldbauer, K. *et al.* Channelrhodopsin-2 is a leaky proton pump. *Proceedings of the National Academy of Sciences of the United States of America* **106**, 12317-12322, doi:Doi 10.1073/Pnas.0905852106 (2009).
124 Papagiakoumou, E. *et al.* Scanless two-photon excitation of channelrhodopsin-2. *Nature methods* **7**, 848-854 (2010).
125 Andrasfalvy, B. K., Zemelman, B. V., Tang, J. & Vaziri, A. Two-photon single-cell optogenetic control of neuronal activity by sculpted light. *Proceedings of the National Academy of Sciences* **107**, 11981-11986 (2010).
126 Packer, A. M., Russell, L. E., Dalgleish, H. W. & Häusser, M. Simultaneous all-optical manipulation and recording of neural circuit activity with cellular resolution in vivo. *Nature methods* **12**, 140-146 (2015).
127 Hernandez, O. *et al.* Three-dimensional spatiotemporal focusing of holographic patterns. *Nature communications* **7**, 1-11 (2016).
128 Accanto, N. *et al.* Multiplexed temporally focused light shaping for high-resolution multi-cell targeting. *Optica* **5**, 1478-1491 (2018).
129 Chaigneau, E. *et al.* Two-photon holographic stimulation of ReaChR. *Frontiers in cellular neuroscience* **10**, 234 (2016).
130 Robinson, N. T. *et al.* Targeted activation of hippocampal place cells drives Memory-Guided spatial behavior. *Cell* **183**, 1586-1599. e1510 (2020).
131 Dalgleish, H. W. *et al.* How many neurons are sufficient for perception of cortical activity? *Elife* **9**, e58889 (2020).
132 Gill, J. V. *et al.* Precise holographic manipulation of olfactory circuits reveals coding features determining perceptual detection. *Neuron* **108**, 382-393. e385 (2020).
133 Dal Maschio, M., Donovan, J. C., Helmbrecht, T. O. & Baier, H. Linking neurons to network function and behavior by two-photon holographic optogenetics and volumetric imaging. *Neuron* **94**, 774-789. e775 (2017).
134 Jennings, J. H. *et al.* Interacting neural ensembles in orbitofrontal cortex for social and feeding behaviour. *Nature* **565**, 645-649 (2019).
135 Accanto, N. *et al.* Multiplexed temporally focused light shaping through a gradient index lens for precise in-depth optogenetic photostimulation. *Scientific reports* **9**, 1-10 (2019).
136 Rowlands, C. J. *et al.* Wide-field three-photon excitation in biological samples. *Light: Science & Applications* **6**, e16255-e16255 (2017).
137 Jackman, S. L., Beneduce, B. M., Drew, I. R. & Regehr, W. G. Achieving high-frequency optical control of synaptic transmission. *Journal of Neuroscience* **34**, 7704-7714 (2014).
138 Cardin, J. A. *et al.* Targeted optogenetic stimulation and recording of neurons in vivo using cell-type-specific expression of Channelrhodopsin-2. *Nature protocols* **5**, 247 (2010).
139 Wu, J. *et al.* Improved orange and red Ca2+ indicators and photophysical considerations for optogenetic applications. *ACS chemical neuroscience* **4**, 963-972 (2013).
140 Platisa, J. & Pieribone, V. A. Genetically encoded fluorescent voltage indicators: are we there yet? *Current opinion in neurobiology* **50**, 146-153 (2018).
141 Urakubo, H., Yagishita, S., Kasai, H., Kubota, Y. & Ishii, S. The critical balance between dopamine D2 receptor and RGS for the sensitive detection of a transient decay in dopamine signal. *PLoS computational biology* **17**, e1009364 (2021).
142 Wang, H., Jing, M. & Li, Y. Lighting up the brain: genetically encoded fluorescent sensors for imaging neurotransmitters and neuromodulators. *Current opinion in neurobiology* **50**, 171-178 (2018).
143 Leopold, A. V., Shcherbakova, D. M. & Verkhusha, V. V. Fluorescent biosensors for neurotransmission and neuromodulation: engineering and applications. *Frontiers in cellular neuroscience* **13**, 474 (2019).

144 Gradinaru, V., Mogri, M., Thompson, K. R., Henderson, J. M. & Deisseroth, K. Optical deconstruction of parkinsonian neural circuitry. *science* **324**, 354-359 (2009).
145 Wu, Y. E., Pan, L., Zuo, Y., Li, X. & Hong, W. Detecting activated cell populations using single-cell RNA-seq. *Neuron* **96**, 313-329. e316 (2017).
146 Franceschini, A., Costantini, I., Pavone, F. S. & Silvestri, L. Dissecting Neuronal Activation on a Brain-Wide Scale With Immediate Early Genes. *Frontiers in Neuroscience* **14**, 1111 (2020).
147 Guenthner, C. J., Miyamichi, K., Yang, H. H., Heller, H. C. & Luo, L. Permanent genetic access to transiently active neurons via TRAP: targeted recombination in active populations. *Neuron* **78**, 773-784 (2013).
148 Grinvald, A., Lieke, E., Frostig, R. D., Gilbert, C. D. & Wiesel, T. N. Functional architecture of cortex revealed by optical imaging of intrinsic signals. *Nature* **324**, 361-364 (1986).
149 Juavinett, A. L., Nauhaus, I., Garrett, M. E., Zhuang, J. & Callaway, E. M. Automated identification of mouse visual areas with intrinsic signal imaging. *Nature protocols* **12**, 32 (2017).
150 Lee, J. H. *et al.* Global and local fMRI signals driven by neurons defined optogenetically by type and wiring. *Nature* **465**, 788-792 (2010).
151 Uludağ, K. & Blinder, P. Linking brain vascular physiology to hemodynamic response in ultra-high field MRI. *Neuroimage* **168**, 279-295 (2018).
152 Albers, F., Wachsmuth, L., Schache, D., Lambers, H. & Faber, C. Functional mri readouts from bold and diffusion measurements differentially respond to optogenetic activation and tissue heating. *Frontiers in neuroscience* **13**, 1104 (2019).
153 Edelman, B. J. & Macé, E. Functional ultrasound brain imaging: bridging networks, neurons and behavior. *Current Opinion in Biomedical Engineering*, 100286 (2021).
154 Brecht, M. *et al.* Organization of rat vibrissa motor cortex and adjacent areas according to cytoarchitectonics, microstimulation, and intracellular stimulation of identified cells. *Journal of Comparative Neurology* **479**, 360-373 (2004).
155 Heindorf, M., Arber, S. & Keller, G. B. Mouse motor cortex coordinates the behavioral response to unpredicted sensory feedback. *Neuron* **99**, 1040-1054. e1045 (2018).
156 Dana, H. *et al.* High-performance calcium sensors for imaging activity in neuronal populations and microcompartments. *Nature methods* **16**, 649-657 (2019).
157 Guo, Z. V. *et al.* Flow of cortical activity underlying a tactile decision in mice. *Neuron* **81**, 179-194 (2014).
158 Jun, J. J. *et al.* Fully integrated silicon probes for high-density recording of neural activity. *Nature* **551**, 232-236 (2017).
159 Steinmetz, N. A. *et al.* Neuropixels 2.0: A miniaturized high-density probe for stable, long-term brain recordings. *Science* **372** (2021).
160 Kvitsiani, D. *et al.* Distinct behavioural and network correlates of two interneuron types in prefrontal cortex. *Nature* **498**, 363-366 (2013).
161 Ferreira-Pinto, M. J. *et al.* Functional diversity for body actions in the mesencephalic locomotor region. *Cell* **184**, 4564-4578. e4518 (2021).
162 Pascoli, V. *et al.* Contrasting forms of cocaine-evoked plasticity control components of relapse. *Nature* **509**, 459-464 (2014).
163 Burguière, E., Monteiro, P., Feng, G. & Graybiel, A. M. Optogenetic stimulation of lateral orbitofronto-striatal pathway suppresses compulsive behaviors. *Science* **340**, 1243-1246 (2013).
164 Hartong, D. T., Berson, E. L. & Dryja, T. P. Retinitis pigmentosa. *The Lancet* **368**, 1795-1809 (2006).
165 de Jong, E. K., Geerlings, M. J. & den Hollander, A. I. Age-related macular degeneration. *Genetics and genomics of eye disease*, 155-180 (2020).
166 Bi, A. *et al.* Ectopic expression of a microbial-type rhodopsin restores visual responses in mice with photoreceptor degeneration. *Neuron* **50**, 23-33 (2006).
167 Sahel, J.-A. *et al.* Partial recovery of visual function in a blind patient after optogenetic therapy. *Nature Medicine*, 1-7 (2021).
168 Tomita, H. *et al.* Restoration of the majority of the visual spectrum by using modified Volvox channelrhodopsin-1. *Molecular Therapy* **22**, 1434-1440 (2014).
169 Sengupta, A. *et al.* Red-shifted channelrhodopsin stimulation restores light responses in blind mice, macaque retina, and human retina. *EMBO molecular medicine* **8**, 1248-1264 (2016).
170 Gauvain, G. *et al.* Optogenetic therapy: high spatiotemporal resolution and pattern discrimination compatible with vision restoration in non-human primates. *Communications biology* **4**, 1-15 (2021).
171 Mattis, J. *et al.* Principles for applying optogenetic tools derived from direct comparative analysis of microbial opsins. *Nature methods* **9**, 159-172 (2012).

172 Ganjawala, T. H., Lu, Q., Fenner, M. D., Abrams, G. W. & Pan, Z.-H. Improved CoChR variants restore visual acuity and contrast sensitivity in a mouse model of blindness under ambient light conditions. *Molecular Therapy* **27**, 1195-1205 (2019).
173 Cehajic-Kapetanovic, J. *et al.* Restoration of vision with ectopic expression of human rod opsin. *Current Biology* **25**, 2111-2122 (2015).
174 Gaub, B. M., Berry, M. H., Holt, A. E., Isacoff, E. Y. & Flannery, J. G. Optogenetic vision restoration using rhodopsin for enhanced sensitivity. *Molecular Therapy* **23**, 1562-1571 (2015).
175 Berry, M. H. *et al.* Restoration of high-sensitivity and adapting vision with a cone opsin. *Nature communications* **10**, 1-12 (2019).
176 van Wyk, M., Pielecka-Fortuna, J., Löwel, S. & Kleinlogel, S. Restoring the ON switch in blind retinas: opto-mGluR6, a next-generation, cell-tailored optogenetic tool. *PLoS Biol* **13**, e1002143 (2015).
177 Surace, E. M. & Auricchio, A. Versatility of AAV vectors for retinal gene transfer. *Vision research* **48**, 353-359 (2008).
178 Ivanova, E., Hwang, G.-S., Pan, Z.-H. & Troilo, D. Evaluation of AAV-mediated expression of Chop2-GFP in the marmoset retina. *Investigative ophthalmology & visual science* **51**, 5288-5296 (2010).
179 Yin, L. *et al.* Intravitreal injection of AAV2 transduces macaque inner retina. *Investigative ophthalmology & visual science* **52**, 2775-2783 (2011).
180 Lagali, P. S. *et al.* Light-activated channels targeted to ON bipolar cells restore visual function in retinal degeneration. *Nature neuroscience* **11**, 667-675 (2008).
181 Cronin, T. *et al.* Efficient transduction and optogenetic stimulation of retinal bipolar cells by a synthetic adeno-associated virus capsid and promoter. *EMBO molecular medicine* **6**, 1175-1190 (2014).
182 Macé, E. *et al.* Targeting channelrhodopsin-2 to ON-bipolar cells with vitreally administered AAV restores ON and OFF visual responses in blind mice. *Molecular Therapy* **23**, 7-16 (2015).
183 Lu, Q., Ganjawala, T. H., Krstevski, A., Abrams, G. W. & Pan, Z.-H. Comparison of AAV-Mediated optogenetic vision restoration between retinal ganglion cell expression and ON bipolar cell targeting. *Molecular Therapy-Methods & Clinical Development* **18**, 15-23 (2020).
184 Busskamp, V. *et al.* Genetic reactivation of cone photoreceptors restores visual responses in retinitis pigmentosa. *science* **329**, 413-417 (2010).
185 Marc, R. E., Jones, B. W., Watt, C. B. & Strettoi, E. Neural remodeling in retinal degeneration. *Progress in retinal and eye research* **22**, 607-655 (2003).
186 Bruegmann, T., Beiert, T., Vogt, C. C., Schrickel, J. W. & Sasse, P. Optogenetic termination of atrial fibrillation in mice. *Cardiovascular research* **114**, 713-723 (2018).
187 Bruegmann, T. *et al.* Optogenetic control of heart muscle in vitro and in vivo. *Nature methods* **7**, 897-900 (2010).
188 Nussinovitch, U. & Gepstein, L. Optogenetics for in vivo cardiac pacing and resynchronization therapies. *Nature biotechnology* **33**, 750-754 (2015).
189 Bruegmann, T. *et al.* Optogenetic defibrillation terminates ventricular arrhythmia in mouse hearts and human simulations. *The Journal of clinical investigation* **126**, 3894-3904 (2016).
190 Boyle, P. M., Williams, J. C., Ambrosi, C. M., Entcheva, E. & Trayanova, N. A. A comprehensive multiscale framework for simulating optogenetics in the heart. *Nature communications* **4**, 1-9 (2013).
191 Quiñonez Uribe, R. A., Luther, S., Diaz-Maue, L. & Richter, C. Energy-reduced arrhythmia termination using global photostimulation in optogenetic murine hearts. *Frontiers in physiology* **9**, 1651 (2018).
192 Nyns, E. C. *et al.* An automated hybrid bioelectronic system for autogenous restoration of sinus rhythm in atrial fibrillation. *Science translational medicine* **11** (2019).
193 Entcheva, E. & Kay, M. W. Cardiac optogenetics: a decade of enlightenment. *Nature Reviews Cardiology* **18**, 349-367 (2021).
194 Zaglia, T. *et al.* Optogenetic determination of the myocardial requirements for extrasystoles by cell type-specific targeting of ChannelRhodopsin-2. *Proceedings of the National Academy of Sciences* **112**, E4495-E4504 (2015).
195 Ambrosi, C. M. & Entcheva, E. Optogenetics 'promise: pacing and cardioversion by light? *Future cardiology* **10**, 1-4 (2014).
196 Williams, J. C. *et al.* Computational optogenetics: empirically-derived voltage-and light-sensitive channelrhodopsin-2 model. *PLoS computational biology* **9**, e1003220 (2013).
197 Karathanos, T. V., Boyle, P. M. & Trayanova, N. A. Optogenetics-enabled dynamic modulation of action potential duration in atrial tissue: feasibility of a novel therapeutic approach. *Europace* **16**, iv69-iv76 (2014).

198 Rajendran, P. S. *et al.* Identification of peripheral neural circuits that regulate heart rate using optogenetic and viral vector strategies. *Nature communications* **10**, 1-13 (2019).
199 Ambrosi, C. M., Sadananda, G., Han, J. L. & Entcheva, E. Adeno-associated virus mediated gene delivery: implications for scalable in vitro and in vivo cardiac optogenetic models. *Frontiers in physiology* **10**, 168 (2019).
200 Wengrowski, A. M. *et al.* Optogenetic release of norepinephrine from cardiac sympathetic neurons alters mechanical and electrical function. *Cardiovascular research* **105**, 143-150 (2015).
201 Moreno, A. *et al.* Sudden heart rate reduction upon optogenetic release of acetylcholine from cardiac parasympathetic neurons in perfused hearts. *Frontiers in physiology* **10**, 16 (2019).
202 Greenberg, B. *et al.* Prevalence of AAV1 neutralizing antibodies and consequences for a clinical trial of gene transfer for advanced heart failure. *Gene therapy* **23**, 313-319 (2016).
203 Crocini, C. *et al.* Optogenetics design of mechanistically-based stimulation patterns for cardiac defibrillation. *Scientific reports* **6**, 1-7 (2016).
204 Hussaini, S. *et al.* Drift and termination of spiral waves in optogenetically modified cardiac tissue at sub-threshold illumination. *Elife* **10**, e59954 (2021).
205 Hochbaum, D. R. *et al.* All-optical electrophysiology in mammalian neurons using engineered microbial rhodopsins. *Nature Methods* **11**, 825-833, doi:Doi 10.1038/Nmeth.3000 (2014).
206 Klimas, A. *et al.* OptoDyCE as an automated system for high-throughput all-optical dynamic cardiac electrophysiology. *Nature communications* **7**, 1-12 (2016).
207 Klimas, A., Ortiz, G., Boggess, S. C., Miller, E. W. & Entcheva, E. Multimodal on-axis platform for all-optical electrophysiology with near-infrared probes in human stem-cell-derived cardiomyocytes. *Progress in biophysics and molecular biology* **154**, 62-70 (2020).
208 Dempsey, G. T. *et al.* Cardiotoxicity screening with simultaneous optogenetic pacing, voltage imaging and calcium imaging. *Journal of pharmacological and toxicological methods* **81**, 240-250 (2016).
209 Dwenger, M. *et al.* Chronic optical pacing conditioning of h-iPSC engineered cardiac tissues. *Journal of tissue engineering* **10**, 2041731419841748 (2019).
210 Quach, B., Krogh-Madsen, T., Entcheva, E. & Christini, D. J. Light-activated dynamic clamp using iPSC-derived cardiomyocytes. *Biophysical journal* **115**, 2206-2217 (2018).
211 Ochoa-Fernandez, R. *et al.* Optogenetic control of gene expression in plants in the presence of ambient white light. *Nature Methods* **17**, 717-725 (2020).
212 Christie, J. M. & Zurbriggen, M. D. Optogenetics in plants. *New Phytologist* **229**, 3108-3115 (2021).
213 Omelina, E. S. *et al.* Optogenetic and Chemical Induction Systems for Regulation of Transgene Expression in Plants: Use in Basic and Applied Research. *International Journal of Molecular Sciences* **23**, 1737 (2022).
214 Papanatsiou, M. *et al.* Optogenetic manipulation of stomatal kinetics improves carbon assimilation, water use, and growth. *Science* **363**, 1456-1459 (2019).
215 Reyer, A. *et al.* Channelrhodopsin-mediated optogenetics highlights a central role of depolarization-dependent plant proton pumps. *Proceedings of the National Academy of Sciences* **117**, 20920-20925 (2020).
216 Zhou, Y. *et al.* Extending the Anion Channelrhodopsin-Based Toolbox for Plant Optogenetics. *Membranes* **11**, 287 (2021).
217 Huang, S. *et al.* Optogenetic control of the guard cell membrane potential and stomatal movement by the light-gated anion channel Gt ACR1. *Science Advances* **7**, eabg4619 (2021).
218 Twell, D., Yamaguchi, J. & McCORMICK, S. Pollen-specific gene expression in transgenic plants: coordinate regulation of two different tomato gene promoters during microsporogenesis. *Development* **109**, 705-713 (1990).
219 Govorunova, E. G., Sineshchekov, O. A., Janz, R., Liu, X. & Spudich, J. L. NEUROSCIENCE. Natural light-gated anion channels: A family of microbial rhodopsins for advanced optogenetics. *Science* **349**, 647-650, doi:10.1126/science.aaa7484 (2015).
220 Gutermuth, T. *et al.* Pollen tube growth regulation by free anions depends on the interaction between the anion channel SLAH3 and calcium-dependent protein kinases CPK2 and CPK20. *The Plant Cell* **25**, 4525-4543 (2013).
221 Gutermuth, T. *et al.* Tip-localized Ca2+-permeable channels control pollen tube growth via kinase-dependent R-and S-type anion channel regulation. *New Phytologist* **218**, 1089-1105 (2018).
222 Gilroy, S. *et al.* ROS, calcium, and electric signals: key mediators of rapid systemic signaling in plants. *Plant physiology* **171**, 1606-1615 (2016).
223 Choi, W. G. *et al.* (Wiley Online Library, 2017).

224 Fromm, J. & Lautner, S. Electrical signals and their physiological significance in plants. *Plant, cell & environment* **30**, 249-257 (2007).
225 Vodeneev, V., Katicheva, L. & Sukhov, V. Electrical signals in higher plants: mechanisms of generation and propagation. *Biophysics* **61**, 505-512 (2016).
226 Szechyńska-Hebda, M., Lewandowska, M. & Karpiński, S. Electrical signaling, photosynthesis and systemic acquired acclimation. *Frontiers in physiology* **8**, 684 (2017).
227 Hedrich, R. & Neher, E. Venus flytrap: how an excitable, carnivorous plant works. *Trends in Plant Science* **23**, 220-234 (2018).
228 Dawydow, A. *et al.* Channelrhodopsin-2–XXL, a powerful optogenetic tool for low-light applications. *Proceedings of the National Academy of Sciences* **111**, 13972-13977 (2014).
229 Inoue, S.-i. & Kinoshita, T. Blue light regulation of stomatal opening and the plasma membrane H+-ATPase. *Plant Physiology* **174**, 531-538 (2017).
230 Pilot, G. *et al.* Guard Cell Inward K+ Channel Activity inArabidopsis Involves Expression of the Twin Channel Subunits KAT1 and KAT2. *Journal of Biological Chemistry* **276**, 3215-3221 (2001).
231 Catterall, W. A., Wisedchaisri, G. & Zheng, N. The chemical basis for electrical signaling. *Nature chemical biology* **13**, 455-463 (2017).
232 Duan, X., Nagel, G. & Gao, S. Mutated channelrhodopsins with increased sodium and calcium permeability. *Applied Sciences* **9**, 664 (2019).
233 Miyashita, T., Shao, Y. R., Chung, J., Pourzia, O. & Feldman, D. Long-term channelrhodopsin-2 (ChR2) expression can induce abnormal axonal morphology and targeting in cerebral cortex. *Frontiers in neural circuits* **7**, 8 (2013).
234 Rapti, K. *et al.* Neutralizing antibodies against AAV serotypes 1, 2, 6, and 9 in sera of commonly used animal models. *Molecular Therapy* **20**, 73-83 (2012).
235 Al-Juboori, S. I. *et al.* Light scattering properties vary across different regions of the adult mouse brain. *PloS one* **8**, e67626 (2013).
236 Shin, Y. *et al.* Characterization of fiber-optic light delivery and light-induced temperature changes in a rodent brain for precise optogenetic neuromodulation. *Biomedical optics express* **7**, 4450-4471 (2016).
237 Arias-Gil, G., Ohl, F. W., Takagaki, K. & Lippert, M. T. Measurement, modeling, and prediction of temperature rise due to optogenetic brain stimulation. *Neurophotonics* **3**, 045007 (2016).
238 Owen, S. F., Liu, M. H. & Kreitzer, A. C. Thermal constraints on in vivo optogenetic manipulations. *Nature neuroscience* **22**, 1061-1065 (2019).
239 Yang, F. & Zheng, J. High temperature sensitivity is intrinsic to voltage-gated potassium channels. *Elife* **3**, e03255 (2014).
240 Sabatini, B. L. & Regehr, W. G. Timing of neurotransmission at fast synapses in the mammalian brain. *Nature* **384**, 170-172 (1996).
241 Moser, E. I. & Andersen, P. Conserved spatial learning in cooled rats in spite of slowing of dentate field potentials. *Journal of Neuroscience* **14**, 4458-4466 (1994).
242 Chen, R. *et al.* Deep brain optogenetics without intracranial surgery. *Nature biotechnology* **39**, 161-164 (2021).
243 Podgorski, K. & Ranganathan, G. Brain heating induced by near-infrared lasers during multiphoton microscopy. *Journal of neurophysiology* **116**, 1012-1023 (2016).
244 Picot, A. *et al.* Temperature rise under two-photon optogenetic brain stimulation. *Cell reports* **24**, 1243-1253. e1245 (2018).
245 Kravitz, A. & Bonci, A. Optogenetics, physiology, and emotions. *Frontiers in behavioral neuroscience* **7**, 169 (2013).
246 Häusser, M. Optogenetics: the age of light. *Nature methods* **11**, 1012-1014 (2014).
247 Chuong, A., Miri, M. & Acker, L. Non-invasive optogenetic neural silencing. *Nat Neurosci* **17**, 1123-1129 (2014).
248 Herman, A. M., Huang, L., Murphey, D. K., Garcia, I. & Arenkiel, B. R. Cell type-specific and time-dependent light exposure contribute to silencing in neurons expressing Channelrhodopsin-2. *Elife* **3**, e01481 (2014).
249 Ferenczi, E. A. *et al.* Optogenetic approaches addressing extracellular modulation of neural excitability. *Scientific reports* **6**, 1-20 (2016).
250 Otchy, T. M. *et al.* Acute off-target effects of neural circuit manipulations. *Nature* **528**, 358-363 (2015).
251 Sorum, B., Rietmeijer, R. A., Gopakumar, K., Adesnik, H. & Brohawn, S. G. Ultrasound activates mechanosensitive TRAAK K+ channels through the lipid membrane. *Proceedings of the National Academy of Sciences* **118** (2021).

252 Strickland, D. *et al.* TULIPs: tunable, light-controlled interacting protein tags for cell biology. *Nature methods* **9**, 379-384 (2012).
253 Kennedy, M. J. *et al.* Rapid blue-light–mediated induction of protein interactions in living cells. *Nature methods* **7**, 973-975 (2010).
254 Levskaya, A., Weiner, O. D., Lim, W. A. & Voigt, C. A. Spatiotemporal control of cell signalling using a light-switchable protein interaction. *Nature* **461**, 997-1001 (2009).
255 Farhi, S. L. *et al.* Wide-area all-optical neurophysiology in acute brain slices. *Journal of Neuroscience* **39**, 4889-4908 (2019).
256 Berndt, A. *et al.* High-efficiency channelrhodopsins for fast neuronal stimulation at low light levels. *Proceedings of the National Academy of Sciences of the United States of America* **108**, 7595-7600, doi:Doi 10.1073/Pnas.1017210108 (2011).
257 Gong, X. *et al.* An ultra-sensitive step-function opsin for minimally invasive optogenetic stimulation in mice and macaques. *Neuron* **107**, 38-51. e38 (2020).

259 Rajasethupathy, P. *et al.* Projections from neocortex mediate top-down control of memory retrieval. *Nature* **526**, 653-659 (2015).
260 Shevchenko, V. *et al.* Inward H+ pump xenorhodopsin: Mechanism and alternative optogenetic approach. *Science advances* **3**, e1603187 (2017).
261 Grimm, C., Silapetere, A., Vogt, A., Sierra, Y. A. B. & Hegemann, P. Electrical properties, substrate specificity and optogenetic potential of the engineered light-driven sodium pump eKR2. *Scientific reports* **8**, 1-12 (2018).
262 Gradinaru, V., Thompson, K. R. & Deisseroth, K. eNpHR: a Natronomonas halorhodopsin enhanced for optogenetic applications. *Brain cell biology* **36**, 129-139 (2008).
263 Subach, O. M. *et al.* FRCaMP, a Red Fluorescent Genetically Encoded Calcium Indicator Based on Calmodulin from Schizosaccharomyces Pombe Fungus. *International Journal of Molecular Sciences* **22**, 111 (2021).
264 Villette, V. *et al.* Ultrafast two-photon imaging of a high-gain voltage indicator in awake behaving mice. *Cell* **179**, 1590-1608. e1523 (2019).
265 Abdelfattah, A. S. *et al.* Bright and photostable chemigenetic indicators for extended in vivo voltage imaging. *Science* **365**, 699-704, doi:10.1126/science.aav6416 (2019).
266 Kannan, M. *et al.* Fast, in vivo voltage imaging using a red fluorescent indicator. *Nature methods* **15**, 1108-1116 (2018).
267 Piatkevich, K. D. *et al.* A robotic multidimensional directed evolution approach applied to fluorescent voltage reporters. *Nature chemical biology* **14**, 352-360 (2018).
268 Miesenböck, G., De Angelis, D. A. & Rothman, J. E. Visualizing secretion and synaptic transmission with pH-sensitive green fluorescent proteins. *Nature* **394**, 192-195 (1998).
269 Anikeeva, P. *et al.* Optetrode: a multichannel readout for optogenetic control in freely moving mice. *Nature neuroscience* **15**, 163-170 (2012).
270 Creed, M., Pascoli, V. J. & Lüscher, C. Refining deep brain stimulation to emulate optogenetic treatment of synaptic pathology. *Science* **347**, 659-664 (2015).
271 Kuhn, J., Gruendler, T. O., Klosterkötter, J. & Bartsch, C. Stimulating the addictive brain. *Frontiers in Human Neuroscience* **6**, 220 (2012).
272 Pan, Z.-H., Lu, Q., Bi, A., Dizhoor, A. M. & Abrams, G. W. Optogenetic approaches to restoring vision. *Annual review of vision science* **1**, 185-210 (2015).

TOC Blurb

Optogenetic techniques involve the introduction of photoreceptors in selected cells to allow control over their activity using light. In this Primer, Emiliani et al. discuss the most commonly used optogenetic tools, illumination approaches and applications in medicine, cardiovascular science and plants, among many other uses.